[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fb3Ac8b7tTWuPD1fgcfRqZkK2AsGmGW4UATQGHC2Pplc":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":85,"rows":92},"Centre Leon Berard",[4],203,false,56,19,53208,53,110,[14,17,20,22,25,27,29,32],{"name":15,"count":16},"Breast Cancer",17,{"name":18,"count":19},"Colorectal Cancer",10,{"name":21,"count":19},"Cancer",{"name":23,"count":24},"Sarcoma",6,{"name":26,"count":24},"Advanced Cancer",{"name":28,"count":24},"Metastatic Cancer",{"name":30,"count":31},"Metastatic Renal Cell Carcinoma",5,{"name":33,"count":34},"Osteosarcoma",4,[36,41,46,51,56,60,65,70,75,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04795661","Immunotherapy in MSI\u002FdMMR Tumors in Perioperative Setting.","2023-10-05","Pembrolizumab",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT05096390","Axitinib +\u002F- Pembrolizumab in First Line Treatment of mPRCC","2024-10","Axitinib Oral Tablet [Inlyta]",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT03375437","RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1\u002F2\u002F3, ROS1 or ALK Gene Fusions.","2024-12-15","Blood and tumor samples",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT05009927","Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (Gist-Ten)","2025-01","Imatinib",{"nctId":57,"briefTitle":58,"date":59,"intervention":50},"NCT01774409","Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer","2025-07",{"nctId":61,"briefTitle":62,"date":63,"intervention":64},"NCT05529251","De-escalation Study for Stage IIa\u002FIIb \u003C 3 cm Seminoma","2025-09-06","Carboplatin AUC7",{"nctId":66,"briefTitle":67,"date":68,"intervention":69},"NCT02029001","Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatment","2026-01","Nilotinib",{"nctId":71,"briefTitle":72,"date":73,"intervention":74},"NCT04698785","Efficacy of Regorafenib Combined With Best Supportive Care as Maintenance Treatment in High Grade Bone Sarcomas Patients","2026-07-21","Treatment by regorafenib and best supportive care",{"nctId":76,"briefTitle":77,"date":78,"intervention":79},"NCT04116541","A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations\u002FCharacteristics in Advanced \u002F Metastatic Tumors.","2026-10","HDM201",{"nctId":81,"briefTitle":82,"date":83,"intervention":84},"NCT04055220","Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas","2026-10-01","Treatment by Regorafenib",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,137,181,199,217,235,253,271,289,319,337,355,373,391,443,484,520,573,609,637,659,697,721,739,762,780,798,819,837,863,881,899,917,935,953,980,998,1016,1034,1052,1070,1088,1106,1124,1150,1178,1204,1222,1240,1266,1296,1348,1373,1399,1434,1459,1485,1503,1532,1550,1574,1592,1610,1636,1662,1685,1711,1729,1757,1781,1799,1817,1866,1895,1924,1955,1983,2001,2019,2045,2071,2089,2114,2132,2150,2175,2198,2225,2243,2261,2279,2304,2330,2348,2372,2395,2420,2438,2456,2480,2505,2529,2547,2570,2588,2613,2640,2658,2684,2708,2734,2752,2775,2793,2811,2836,2863,2881,2905,2929,2947,2973,2991,3019,3037,3055,3078,3096,3121,3139,3164,3190,3213,3239,3268,3286,3311,3329,3356,3381,3404],{"intervention":94,"totalTrials":95,"cells":96},"Cetuximab",2,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":114,"PHASE4":133,"NA":135},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[104],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":109,"start":109,"enrollment":99,"conditions":110,"interventions":112},"NCT02014831","Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)","WITHDRAWN",[88],"2016-02",[111],"Squamous Cell Carcinoma of the Penis",[94,113],"TIP",{"trials":115,"activeCount":132,"soonestReadout":121},[116],{"nctId":117,"briefTitle":118,"status":119,"phases":120,"primaryCompletion":121,"completion":121,"start":122,"enrollment":123,"conditions":124,"interventions":129},"NCT06706401","Lymphocyte-Sparing And Radio-Immunotherapy in Head and Neck Carcinoma","RECRUITING",[89],"2029-01","2025-02-20",460,[125,126,127,128],"Oropharynx Cancer","Larynx Cancer","Hypopharynx Cancer","Primary Head and Neck Tumor",[130,131,94],"Vesanoid","Cisplatin",1,{"trials":134,"activeCount":99},[],{"trials":136,"activeCount":99},[],{"intervention":138,"totalTrials":95,"cells":139},"Nivolumab",{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":160,"PHASE4":177,"NA":179},{"trials":141,"activeCount":99},[],{"trials":143,"activeCount":99},[],{"trials":145,"activeCount":99},[146],{"nctId":147,"briefTitle":148,"status":149,"phases":150,"primaryCompletion":151,"completion":152,"start":153,"enrollment":154,"conditions":155,"interventions":157},"NCT03818685","Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease","UNKNOWN",[88],"2024-03-15","2024-05-01","2019-07-02",95,[15,156],"Triple Negative Breast Neoplasms",[138,158,159],"Ipilimumab","Capecitabine",{"trials":161,"activeCount":132,"soonestReadout":166},[162],{"nctId":163,"briefTitle":164,"status":119,"phases":165,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":172},"NCT06346197","Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI\u002FdMMR Esogastric Adenocarcinomas",[89],"2028-05-15","2025-12-08",132,[170,171,28,26],"Gastric Cancer","MSI-H",[173,174,175,176,138],"Balstilimab","Botensilimab","Folfox Protocol","XELOX",{"trials":178,"activeCount":99},[],{"trials":180,"activeCount":99},[],{"intervention":173,"totalTrials":132,"cells":182},{"EARLY_PHASE1":183,"PHASE1":185,"PHASE2":187,"PHASE3":189,"PHASE4":195,"NA":197},{"trials":184,"activeCount":99},[],{"trials":186,"activeCount":99},[],{"trials":188,"activeCount":99},[],{"trials":190,"activeCount":132,"soonestReadout":166},[191],{"nctId":163,"briefTitle":164,"status":119,"phases":192,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":193,"interventions":194},[89],[170,171,28,26],[173,174,175,176,138],{"trials":196,"activeCount":99},[],{"trials":198,"activeCount":99},[],{"intervention":174,"totalTrials":132,"cells":200},{"EARLY_PHASE1":201,"PHASE1":203,"PHASE2":205,"PHASE3":207,"PHASE4":213,"NA":215},{"trials":202,"activeCount":99},[],{"trials":204,"activeCount":99},[],{"trials":206,"activeCount":99},[],{"trials":208,"activeCount":132,"soonestReadout":166},[209],{"nctId":163,"briefTitle":164,"status":119,"phases":210,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":211,"interventions":212},[89],[170,171,28,26],[173,174,175,176,138],{"trials":214,"activeCount":99},[],{"trials":216,"activeCount":99},[],{"intervention":175,"totalTrials":132,"cells":218},{"EARLY_PHASE1":219,"PHASE1":221,"PHASE2":223,"PHASE3":225,"PHASE4":231,"NA":233},{"trials":220,"activeCount":99},[],{"trials":222,"activeCount":99},[],{"trials":224,"activeCount":99},[],{"trials":226,"activeCount":132,"soonestReadout":166},[227],{"nctId":163,"briefTitle":164,"status":119,"phases":228,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":229,"interventions":230},[89],[170,171,28,26],[173,174,175,176,138],{"trials":232,"activeCount":99},[],{"trials":234,"activeCount":99},[],{"intervention":176,"totalTrials":132,"cells":236},{"EARLY_PHASE1":237,"PHASE1":239,"PHASE2":241,"PHASE3":243,"PHASE4":249,"NA":251},{"trials":238,"activeCount":99},[],{"trials":240,"activeCount":99},[],{"trials":242,"activeCount":99},[],{"trials":244,"activeCount":132,"soonestReadout":166},[245],{"nctId":163,"briefTitle":164,"status":119,"phases":246,"primaryCompletion":166,"completion":166,"start":167,"enrollment":168,"conditions":247,"interventions":248},[89],[170,171,28,26],[173,174,175,176,138],{"trials":250,"activeCount":99},[],{"trials":252,"activeCount":99},[],{"intervention":130,"totalTrials":132,"cells":254},{"EARLY_PHASE1":255,"PHASE1":257,"PHASE2":259,"PHASE3":261,"PHASE4":267,"NA":269},{"trials":256,"activeCount":99},[],{"trials":258,"activeCount":99},[],{"trials":260,"activeCount":99},[],{"trials":262,"activeCount":132,"soonestReadout":121},[263],{"nctId":117,"briefTitle":118,"status":119,"phases":264,"primaryCompletion":121,"completion":121,"start":122,"enrollment":123,"conditions":265,"interventions":266},[89],[125,126,127,128],[130,131,94],{"trials":268,"activeCount":99},[],{"trials":270,"activeCount":99},[],{"intervention":131,"totalTrials":132,"cells":272},{"EARLY_PHASE1":273,"PHASE1":275,"PHASE2":277,"PHASE3":279,"PHASE4":285,"NA":287},{"trials":274,"activeCount":99},[],{"trials":276,"activeCount":99},[],{"trials":278,"activeCount":99},[],{"trials":280,"activeCount":132,"soonestReadout":121},[281],{"nctId":117,"briefTitle":118,"status":119,"phases":282,"primaryCompletion":121,"completion":121,"start":122,"enrollment":123,"conditions":283,"interventions":284},[89],[125,126,127,128],[130,131,94],{"trials":286,"activeCount":99},[],{"trials":288,"activeCount":99},[],{"intervention":290,"totalTrials":132,"cells":291},"16 weeks of VEC + CDDP",{"EARLY_PHASE1":292,"PHASE1":294,"PHASE2":296,"PHASE3":298,"PHASE4":315,"NA":317},{"trials":293,"activeCount":99},[],{"trials":295,"activeCount":99},[],{"trials":297,"activeCount":99},[],{"trials":299,"activeCount":132,"soonestReadout":304},[300],{"nctId":301,"briefTitle":302,"status":119,"phases":303,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":310},"NCT02265770","An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma",[88,89],"2028-06","2031-08","2015-06-02",536,[309],"Childhood Ependymoma",[290,311,312,313,314],"VEC + HD-MTX","Chemotherapy + Valproate","VEC","Chemotherapy",{"trials":316,"activeCount":99},[],{"trials":318,"activeCount":99},[],{"intervention":311,"totalTrials":132,"cells":320},{"EARLY_PHASE1":321,"PHASE1":323,"PHASE2":325,"PHASE3":327,"PHASE4":333,"NA":335},{"trials":322,"activeCount":99},[],{"trials":324,"activeCount":99},[],{"trials":326,"activeCount":99},[],{"trials":328,"activeCount":132,"soonestReadout":304},[329],{"nctId":301,"briefTitle":302,"status":119,"phases":330,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":331,"interventions":332},[88,89],[309],[290,311,312,313,314],{"trials":334,"activeCount":99},[],{"trials":336,"activeCount":99},[],{"intervention":312,"totalTrials":132,"cells":338},{"EARLY_PHASE1":339,"PHASE1":341,"PHASE2":343,"PHASE3":345,"PHASE4":351,"NA":353},{"trials":340,"activeCount":99},[],{"trials":342,"activeCount":99},[],{"trials":344,"activeCount":99},[],{"trials":346,"activeCount":132,"soonestReadout":304},[347],{"nctId":301,"briefTitle":302,"status":119,"phases":348,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":349,"interventions":350},[88,89],[309],[290,311,312,313,314],{"trials":352,"activeCount":99},[],{"trials":354,"activeCount":99},[],{"intervention":313,"totalTrials":132,"cells":356},{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":369,"NA":371},{"trials":358,"activeCount":99},[],{"trials":360,"activeCount":99},[],{"trials":362,"activeCount":99},[],{"trials":364,"activeCount":132,"soonestReadout":304},[365],{"nctId":301,"briefTitle":302,"status":119,"phases":366,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":367,"interventions":368},[88,89],[309],[290,311,312,313,314],{"trials":370,"activeCount":99},[],{"trials":372,"activeCount":99},[],{"intervention":314,"totalTrials":132,"cells":374},{"EARLY_PHASE1":375,"PHASE1":377,"PHASE2":379,"PHASE3":381,"PHASE4":387,"NA":389},{"trials":376,"activeCount":99},[],{"trials":378,"activeCount":99},[],{"trials":380,"activeCount":99},[],{"trials":382,"activeCount":132,"soonestReadout":304},[383],{"nctId":301,"briefTitle":302,"status":119,"phases":384,"primaryCompletion":304,"completion":305,"start":306,"enrollment":307,"conditions":385,"interventions":386},[88,89],[309],[290,311,312,313,314],{"trials":388,"activeCount":99},[],{"trials":390,"activeCount":99},[],{"intervention":392,"totalTrials":393,"cells":394},"Pazopanib",3,{"EARLY_PHASE1":395,"PHASE1":397,"PHASE2":399,"PHASE3":437,"PHASE4":439,"NA":441},{"trials":396,"activeCount":99},[],{"trials":398,"activeCount":99},[],{"trials":400,"activeCount":95,"soonestReadout":68},[401,413,424],{"nctId":402,"briefTitle":403,"status":404,"phases":405,"primaryCompletion":406,"completion":406,"start":407,"enrollment":408,"conditions":409,"interventions":412},"NCT05180695","HDM201 and Pazopanib in Patients With P53 Wild-type Advanced\u002FMetastatic Soft Tissue Sarcomas","ACTIVE_NOT_RECRUITING",[87,88],"2027-02","2022-04-15",47,[410,411],"Advanced Soft-tissue Sarcoma","Metastatic Soft-tissue Sarcoma",[392,79],{"nctId":414,"briefTitle":415,"status":416,"phases":417,"primaryCompletion":418,"completion":109,"start":419,"enrollment":420,"conditions":421,"interventions":423},"NCT01323400","Efficacy of Pazopanib in Gastrointestinal Stromal Tumors (GIST)","COMPLETED",[88],"2014-04","2011-03",81,[422],"GIST",[392],{"nctId":66,"briefTitle":67,"status":119,"phases":425,"primaryCompletion":68,"completion":426,"start":427,"enrollment":428,"conditions":429,"interventions":431},[88],"2027-10","2014-03",900,[430],"Malignant Solid Neoplasms",[69,432,433,434,392,435,436],"Everolimus","Sorafenib","Lapatinib","Olaparib","Durvalumab + Tremelimumab",{"trials":438,"activeCount":99},[],{"trials":440,"activeCount":99},[],{"trials":442,"activeCount":99},[],{"intervention":79,"totalTrials":393,"cells":444},{"EARLY_PHASE1":445,"PHASE1":447,"PHASE2":459,"PHASE3":478,"PHASE4":480,"NA":482},{"trials":446,"activeCount":99},[],{"trials":448,"activeCount":99},[449],{"nctId":450,"briefTitle":451,"status":416,"phases":452,"primaryCompletion":453,"completion":453,"start":454,"enrollment":455,"conditions":456,"interventions":457},"NCT03714958","Trametinib + HDM201 in CRC Patients With RAS\u002FRAF Mutant and TP53 Wild-type Advanced\u002FMetastatic Colorectal Cancer Mutant and TP53 Wild-type",[87],"2023-09-12","2018-12-20",12,[18,26,28],[79,458],"Trametinib",{"trials":460,"activeCount":95,"soonestReadout":78},[461,465],{"nctId":402,"briefTitle":403,"status":404,"phases":462,"primaryCompletion":406,"completion":406,"start":407,"enrollment":408,"conditions":463,"interventions":464},[87,88],[410,411],[392,79],{"nctId":76,"briefTitle":77,"status":119,"phases":466,"primaryCompletion":78,"completion":426,"start":467,"enrollment":468,"conditions":469,"interventions":471},[88],"2020-01-28",455,[470],"Malignant Solid Tumor",[79,472,473,474,475,458,476,477],"Ribociclib","Cabozantinib","Alectinib","Regorafenib","Dabrafenib","Avapritinib",{"trials":479,"activeCount":99},[],{"trials":481,"activeCount":99},[],{"trials":483,"activeCount":99},[],{"intervention":55,"totalTrials":95,"cells":485},{"EARLY_PHASE1":486,"PHASE1":488,"PHASE2":490,"PHASE3":514,"PHASE4":516,"NA":518},{"trials":487,"activeCount":99},[],{"trials":489,"activeCount":99},[],{"trials":491,"activeCount":95,"soonestReadout":54},[492,504],{"nctId":493,"briefTitle":494,"status":404,"phases":495,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":499,"interventions":502},"NCT04070443","Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase",[88],"2029-06-01","2019-11-13",170,[500,501],"Philadelphia Chromosome Positive CML","BCR-ABL Positive Chronic Myelogenous Leukemia",[503,55],"Ponatinib",{"nctId":52,"briefTitle":53,"status":119,"phases":505,"primaryCompletion":54,"completion":506,"start":507,"enrollment":508,"conditions":509,"interventions":513},[88],"2027-01","2022-01-03",50,[510,511,512],"Metastatic Gastrointestinal Stromal Tumor (GIST)","C-KIT Mutation","Advanced Gastrointestinal Stromal Tumor (GIST)",[55],{"trials":515,"activeCount":99},[],{"trials":517,"activeCount":99},[],{"trials":519,"activeCount":99},[],{"intervention":521,"totalTrials":393,"cells":522},"Temozolomide",{"EARLY_PHASE1":523,"PHASE1":525,"PHASE2":527,"PHASE3":557,"PHASE4":569,"NA":571},{"trials":524,"activeCount":99},[],{"trials":526,"activeCount":99},[],{"trials":528,"activeCount":132,"soonestReadout":533},[529,543],{"nctId":530,"briefTitle":531,"status":119,"phases":532,"primaryCompletion":533,"completion":534,"start":535,"enrollment":536,"conditions":537,"interventions":541},"NCT07243470","Combination of Tarlatamab and Temozolomide in Patients With Central Nervous System Tumors",[87,88],"2029-10","2030-10","2025-11-04",70,[538,539,540],"Glioma","CNS Tumor, Adult","CNS Tumor, Childhood",[542,521],"Tarlatamab",{"nctId":544,"briefTitle":545,"status":546,"phases":547,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":552,"interventions":555},"NCT01601184","Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway","TERMINATED",[87,88],"2017-09","2017-10","2012-06",24,[553,554],"Histologically Confirmed Medulloblastoma","Activation of the Sonic Hedgehog (SHH) Pathway",[556,521],"vismodegib",{"trials":558,"activeCount":99},[559],{"nctId":560,"briefTitle":561,"status":416,"phases":562,"primaryCompletion":563,"start":564,"enrollment":536,"conditions":565,"interventions":567},"NCT00820963","Standard Radiation Therapy, Higher-Dose Radiation Therapy, or Chemotherapy in Treating Older Patients With Glioblastoma Multiforme",[89],"2011-05","2006-07",[566],"Brain and Central Nervous System Tumors",[568],"temozolomide",{"trials":570,"activeCount":99},[],{"trials":572,"activeCount":99},[],{"intervention":40,"totalTrials":95,"cells":574},{"EARLY_PHASE1":575,"PHASE1":577,"PHASE2":593,"PHASE3":603,"PHASE4":605,"NA":607},{"trials":576,"activeCount":99},[],{"trials":578,"activeCount":99},[579],{"nctId":580,"briefTitle":581,"status":416,"phases":582,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":591},"NCT03871959","Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced\u002FMetastatic Adenocarcinoma",[87],"2022-05-30","2022-06-08","2019-09-15",54,[588,589,590],"Adenocarcinoma of the Pancreas","Adenocarcinoma of the Colon","Adenocarcinoma of the Rectum",[40,592],"DEBIO1143",{"trials":594,"activeCount":132,"soonestReadout":39},[595],{"nctId":37,"briefTitle":38,"status":404,"phases":596,"primaryCompletion":39,"completion":533,"start":597,"enrollment":598,"conditions":599,"interventions":602},[88],"2021-10-18",240,[600,601],"Localized Resectable Tumor","MSI\u002FdMMR",[40],{"trials":604,"activeCount":99},[],{"trials":606,"activeCount":99},[],{"trials":608,"activeCount":99},[],{"intervention":473,"totalTrials":95,"cells":610},{"EARLY_PHASE1":611,"PHASE1":613,"PHASE2":615,"PHASE3":631,"PHASE4":633,"NA":635},{"trials":612,"activeCount":99},[],{"trials":614,"activeCount":99},[],{"trials":616,"activeCount":132,"soonestReadout":78},[617,621],{"nctId":76,"briefTitle":77,"status":119,"phases":618,"primaryCompletion":78,"completion":426,"start":467,"enrollment":468,"conditions":619,"interventions":620},[88],[470],[79,472,473,474,475,458,476,477],{"nctId":622,"briefTitle":623,"status":416,"phases":624,"primaryCompletion":625,"completion":626,"start":627,"enrollment":628,"conditions":629,"interventions":630},"NCT03967522","Evaluation of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC) With Brain Metastases",[88],"2024-10-22","2024-11-01","2019-11-29",26,[30],[473],{"trials":632,"activeCount":99},[],{"trials":634,"activeCount":99},[],{"trials":636,"activeCount":99},[],{"intervention":458,"totalTrials":95,"cells":638},{"EARLY_PHASE1":639,"PHASE1":641,"PHASE2":647,"PHASE3":653,"PHASE4":655,"NA":657},{"trials":640,"activeCount":99},[],{"trials":642,"activeCount":99},[643],{"nctId":450,"briefTitle":451,"status":416,"phases":644,"primaryCompletion":453,"completion":453,"start":454,"enrollment":455,"conditions":645,"interventions":646},[87],[18,26,28],[79,458],{"trials":648,"activeCount":132,"soonestReadout":78},[649],{"nctId":76,"briefTitle":77,"status":119,"phases":650,"primaryCompletion":78,"completion":426,"start":467,"enrollment":468,"conditions":651,"interventions":652},[88],[470],[79,472,473,474,475,458,476,477],{"trials":654,"activeCount":99},[],{"trials":656,"activeCount":99},[],{"trials":658,"activeCount":99},[],{"intervention":660,"totalTrials":95,"cells":661},"NP137",{"EARLY_PHASE1":662,"PHASE1":664,"PHASE2":666,"PHASE3":691,"PHASE4":693,"NA":695},{"trials":663,"activeCount":99},[],{"trials":665,"activeCount":99},[],{"trials":667,"activeCount":132,"soonestReadout":672},[668,680],{"nctId":669,"briefTitle":670,"status":404,"phases":671,"primaryCompletion":672,"completion":672,"start":673,"enrollment":674,"conditions":675,"interventions":678},"NCT05605496","NP137 Clinical and Biological Activities Assessment in Patients With Advanced\u002FMetastatic Solid Tumors Treated by Standard Anti PD-1\u002FPD-L1 Immunotherapies",[88],"2027-01-01","2023-01-06",57,[676,677],"Advanced Solid Tumors","Metastatic Solid Tumors",[660,679],"anti-PD-1\u002FPD-L1",{"nctId":681,"briefTitle":682,"status":546,"phases":683,"primaryCompletion":684,"completion":684,"start":685,"enrollment":132,"conditions":686,"interventions":688},"NCT06150040","Acute Myeloid Leukemia Treated With With NETrin Abs in Combination With [AZACITIDINE + VENETOCLAX]",[87,88],"2025-02-18","2024-09-11",[687],"Acute Myeloid Leukemia Refractory",[660,689,690],"Azacitidine","Venetoclax",{"trials":692,"activeCount":99},[],{"trials":694,"activeCount":99},[],{"trials":696,"activeCount":99},[],{"intervention":64,"totalTrials":132,"cells":698},{"EARLY_PHASE1":699,"PHASE1":701,"PHASE2":703,"PHASE3":715,"PHASE4":717,"NA":719},{"trials":700,"activeCount":99},[],{"trials":702,"activeCount":99},[],{"trials":704,"activeCount":132,"soonestReadout":63},[705],{"nctId":61,"briefTitle":62,"status":119,"phases":706,"primaryCompletion":63,"completion":707,"start":708,"enrollment":709,"conditions":710,"interventions":713},[88],"2030-09-06","2022-09-06",90,[711,712],"Seminoma","Stage II",[64,714],"3 cycles of EP",{"trials":716,"activeCount":99},[],{"trials":718,"activeCount":99},[],{"trials":720,"activeCount":99},[],{"intervention":714,"totalTrials":132,"cells":722},{"EARLY_PHASE1":723,"PHASE1":725,"PHASE2":727,"PHASE3":733,"PHASE4":735,"NA":737},{"trials":724,"activeCount":99},[],{"trials":726,"activeCount":99},[],{"trials":728,"activeCount":132,"soonestReadout":63},[729],{"nctId":61,"briefTitle":62,"status":119,"phases":730,"primaryCompletion":63,"completion":707,"start":708,"enrollment":709,"conditions":731,"interventions":732},[88],[711,712],[64,714],{"trials":734,"activeCount":99},[],{"trials":736,"activeCount":99},[],{"trials":738,"activeCount":99},[],{"intervention":45,"totalTrials":132,"cells":740},{"EARLY_PHASE1":741,"PHASE1":743,"PHASE2":745,"PHASE3":756,"PHASE4":758,"NA":760},{"trials":742,"activeCount":99},[],{"trials":744,"activeCount":99},[],{"trials":746,"activeCount":132,"soonestReadout":44},[747],{"nctId":42,"briefTitle":43,"status":119,"phases":748,"primaryCompletion":44,"completion":749,"start":750,"enrollment":751,"conditions":752,"interventions":754},[88],"2026-06","2022-06-01",72,[753],"Papillary Renal Cell Carcinoma Type 2",[45,755],"Pembrolizumab Injection [Keytruda]",{"trials":757,"activeCount":99},[],{"trials":759,"activeCount":99},[],{"trials":761,"activeCount":99},[],{"intervention":755,"totalTrials":132,"cells":763},{"EARLY_PHASE1":764,"PHASE1":766,"PHASE2":768,"PHASE3":774,"PHASE4":776,"NA":778},{"trials":765,"activeCount":99},[],{"trials":767,"activeCount":99},[],{"trials":769,"activeCount":132,"soonestReadout":44},[770],{"nctId":42,"briefTitle":43,"status":119,"phases":771,"primaryCompletion":44,"completion":749,"start":750,"enrollment":751,"conditions":772,"interventions":773},[88],[753],[45,755],{"trials":775,"activeCount":99},[],{"trials":777,"activeCount":99},[],{"trials":779,"activeCount":99},[],{"intervention":542,"totalTrials":132,"cells":781},{"EARLY_PHASE1":782,"PHASE1":784,"PHASE2":786,"PHASE3":792,"PHASE4":794,"NA":796},{"trials":783,"activeCount":99},[],{"trials":785,"activeCount":99},[],{"trials":787,"activeCount":132,"soonestReadout":533},[788],{"nctId":530,"briefTitle":531,"status":119,"phases":789,"primaryCompletion":533,"completion":534,"start":535,"enrollment":536,"conditions":790,"interventions":791},[87,88],[538,539,540],[542,521],{"trials":793,"activeCount":99},[],{"trials":795,"activeCount":99},[],{"trials":797,"activeCount":99},[],{"intervention":74,"totalTrials":132,"cells":799},{"EARLY_PHASE1":800,"PHASE1":802,"PHASE2":804,"PHASE3":813,"PHASE4":815,"NA":817},{"trials":801,"activeCount":99},[],{"trials":803,"activeCount":99},[],{"trials":805,"activeCount":132,"soonestReadout":73},[806],{"nctId":71,"briefTitle":72,"status":119,"phases":807,"primaryCompletion":73,"completion":73,"start":808,"enrollment":809,"conditions":810,"interventions":812},[88],"2021-07-21",36,[811,33],"Bone Sarcoma",[74],{"trials":814,"activeCount":99},[],{"trials":816,"activeCount":99},[],{"trials":818,"activeCount":99},[],{"intervention":503,"totalTrials":132,"cells":820},{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":831,"PHASE4":833,"NA":835},{"trials":822,"activeCount":99},[],{"trials":824,"activeCount":99},[],{"trials":826,"activeCount":132,"soonestReadout":496},[827],{"nctId":493,"briefTitle":494,"status":404,"phases":828,"primaryCompletion":496,"completion":496,"start":497,"enrollment":498,"conditions":829,"interventions":830},[88],[500,501],[503,55],{"trials":832,"activeCount":99},[],{"trials":834,"activeCount":99},[],{"trials":836,"activeCount":99},[],{"intervention":838,"totalTrials":132,"cells":839},"Aromatase Inhibitors",{"EARLY_PHASE1":840,"PHASE1":842,"PHASE2":844,"PHASE3":857,"PHASE4":859,"NA":861},{"trials":841,"activeCount":99},[],{"trials":843,"activeCount":99},[],{"trials":845,"activeCount":132,"soonestReadout":850},[846],{"nctId":847,"briefTitle":848,"status":119,"phases":849,"primaryCompletion":850,"completion":851,"start":852,"enrollment":853,"conditions":854,"interventions":856},"NCT03624244","Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced\u002F Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)",[88],"2028-01","2031-01","2019-01-23",40,[855],"Low Grade Endometrial Stromal Sarcoma",[838],{"trials":858,"activeCount":99},[],{"trials":860,"activeCount":99},[],{"trials":862,"activeCount":99},[],{"intervention":472,"totalTrials":132,"cells":864},{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":875,"PHASE4":877,"NA":879},{"trials":866,"activeCount":99},[],{"trials":868,"activeCount":99},[],{"trials":870,"activeCount":132,"soonestReadout":78},[871],{"nctId":76,"briefTitle":77,"status":119,"phases":872,"primaryCompletion":78,"completion":426,"start":467,"enrollment":468,"conditions":873,"interventions":874},[88],[470],[79,472,473,474,475,458,476,477],{"trials":876,"activeCount":99},[],{"trials":878,"activeCount":99},[],{"trials":880,"activeCount":99},[],{"intervention":474,"totalTrials":132,"cells":882},{"EARLY_PHASE1":883,"PHASE1":885,"PHASE2":887,"PHASE3":893,"PHASE4":895,"NA":897},{"trials":884,"activeCount":99},[],{"trials":886,"activeCount":99},[],{"trials":888,"activeCount":132,"soonestReadout":78},[889],{"nctId":76,"briefTitle":77,"status":119,"phases":890,"primaryCompletion":78,"completion":426,"start":467,"enrollment":468,"conditions":891,"interventions":892},[88],[470],[79,472,473,474,475,458,476,477],{"trials":894,"activeCount":99},[],{"trials":896,"activeCount":99},[],{"trials":898,"activeCount":99},[],{"intervention":475,"totalTrials":132,"cells":900},{"EARLY_PHASE1":901,"PHASE1":903,"PHASE2":905,"PHASE3":911,"PHASE4":913,"NA":915},{"trials":902,"activeCount":99},[],{"trials":904,"activeCount":99},[],{"trials":906,"activeCount":132,"soonestReadout":78},[907],{"nctId":76,"briefTitle":77,"status":119,"phases":908,"primaryCompletion":78,"completion":426,"start":467,"enrollment":468,"conditions":909,"interventions":910},[88],[470],[79,472,473,474,475,458,476,477],{"trials":912,"activeCount":99},[],{"trials":914,"activeCount":99},[],{"trials":916,"activeCount":99},[],{"intervention":476,"totalTrials":132,"cells":918},{"EARLY_PHASE1":919,"PHASE1":921,"PHASE2":923,"PHASE3":929,"PHASE4":931,"NA":933},{"trials":920,"activeCount":99},[],{"trials":922,"activeCount":99},[],{"trials":924,"activeCount":132,"soonestReadout":78},[925],{"nctId":76,"briefTitle":77,"status":119,"phases":926,"primaryCompletion":78,"completion":426,"start":467,"enrollment":468,"conditions":927,"interventions":928},[88],[470],[79,472,473,474,475,458,476,477],{"trials":930,"activeCount":99},[],{"trials":932,"activeCount":99},[],{"trials":934,"activeCount":99},[],{"intervention":477,"totalTrials":132,"cells":936},{"EARLY_PHASE1":937,"PHASE1":939,"PHASE2":941,"PHASE3":947,"PHASE4":949,"NA":951},{"trials":938,"activeCount":99},[],{"trials":940,"activeCount":99},[],{"trials":942,"activeCount":132,"soonestReadout":78},[943],{"nctId":76,"briefTitle":77,"status":119,"phases":944,"primaryCompletion":78,"completion":426,"start":467,"enrollment":468,"conditions":945,"interventions":946},[88],[470],[79,472,473,474,475,458,476,477],{"trials":948,"activeCount":99},[],{"trials":950,"activeCount":99},[],{"trials":952,"activeCount":99},[],{"intervention":954,"totalTrials":132,"cells":955},"Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery",{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":960,"PHASE3":974,"PHASE4":976,"NA":978},{"trials":957,"activeCount":99},[],{"trials":959,"activeCount":99},[],{"trials":961,"activeCount":132,"soonestReadout":966},[962],{"nctId":963,"briefTitle":964,"status":404,"phases":965,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":969,"interventions":971},"NCT03474094","Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy",[88],"2026-12-30","2018-08-01",62,[970],"Sarcoma,Soft Tissue",[954,972,973],"2 cycles of atezolizumab followed by surgery then post-operative radiotherapy","Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.",{"trials":975,"activeCount":99},[],{"trials":977,"activeCount":99},[],{"trials":979,"activeCount":99},[],{"intervention":972,"totalTrials":132,"cells":981},{"EARLY_PHASE1":982,"PHASE1":984,"PHASE2":986,"PHASE3":992,"PHASE4":994,"NA":996},{"trials":983,"activeCount":99},[],{"trials":985,"activeCount":99},[],{"trials":987,"activeCount":132,"soonestReadout":966},[988],{"nctId":963,"briefTitle":964,"status":404,"phases":989,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":990,"interventions":991},[88],[970],[954,972,973],{"trials":993,"activeCount":99},[],{"trials":995,"activeCount":99},[],{"trials":997,"activeCount":99},[],{"intervention":973,"totalTrials":132,"cells":999},{"EARLY_PHASE1":1000,"PHASE1":1002,"PHASE2":1004,"PHASE3":1010,"PHASE4":1012,"NA":1014},{"trials":1001,"activeCount":99},[],{"trials":1003,"activeCount":99},[],{"trials":1005,"activeCount":132,"soonestReadout":966},[1006],{"nctId":963,"briefTitle":964,"status":404,"phases":1007,"primaryCompletion":966,"completion":966,"start":967,"enrollment":968,"conditions":1008,"interventions":1009},[88],[970],[954,972,973],{"trials":1011,"activeCount":99},[],{"trials":1013,"activeCount":99},[],{"trials":1015,"activeCount":99},[],{"intervention":69,"totalTrials":132,"cells":1017},{"EARLY_PHASE1":1018,"PHASE1":1020,"PHASE2":1022,"PHASE3":1028,"PHASE4":1030,"NA":1032},{"trials":1019,"activeCount":99},[],{"trials":1021,"activeCount":99},[],{"trials":1023,"activeCount":132,"soonestReadout":68},[1024],{"nctId":66,"briefTitle":67,"status":119,"phases":1025,"primaryCompletion":68,"completion":426,"start":427,"enrollment":428,"conditions":1026,"interventions":1027},[88],[430],[69,432,433,434,392,435,436],{"trials":1029,"activeCount":99},[],{"trials":1031,"activeCount":99},[],{"trials":1033,"activeCount":99},[],{"intervention":432,"totalTrials":132,"cells":1035},{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1040,"PHASE3":1046,"PHASE4":1048,"NA":1050},{"trials":1037,"activeCount":99},[],{"trials":1039,"activeCount":99},[],{"trials":1041,"activeCount":132,"soonestReadout":68},[1042],{"nctId":66,"briefTitle":67,"status":119,"phases":1043,"primaryCompletion":68,"completion":426,"start":427,"enrollment":428,"conditions":1044,"interventions":1045},[88],[430],[69,432,433,434,392,435,436],{"trials":1047,"activeCount":99},[],{"trials":1049,"activeCount":99},[],{"trials":1051,"activeCount":99},[],{"intervention":433,"totalTrials":132,"cells":1053},{"EARLY_PHASE1":1054,"PHASE1":1056,"PHASE2":1058,"PHASE3":1064,"PHASE4":1066,"NA":1068},{"trials":1055,"activeCount":99},[],{"trials":1057,"activeCount":99},[],{"trials":1059,"activeCount":132,"soonestReadout":68},[1060],{"nctId":66,"briefTitle":67,"status":119,"phases":1061,"primaryCompletion":68,"completion":426,"start":427,"enrollment":428,"conditions":1062,"interventions":1063},[88],[430],[69,432,433,434,392,435,436],{"trials":1065,"activeCount":99},[],{"trials":1067,"activeCount":99},[],{"trials":1069,"activeCount":99},[],{"intervention":434,"totalTrials":132,"cells":1071},{"EARLY_PHASE1":1072,"PHASE1":1074,"PHASE2":1076,"PHASE3":1082,"PHASE4":1084,"NA":1086},{"trials":1073,"activeCount":99},[],{"trials":1075,"activeCount":99},[],{"trials":1077,"activeCount":132,"soonestReadout":68},[1078],{"nctId":66,"briefTitle":67,"status":119,"phases":1079,"primaryCompletion":68,"completion":426,"start":427,"enrollment":428,"conditions":1080,"interventions":1081},[88],[430],[69,432,433,434,392,435,436],{"trials":1083,"activeCount":99},[],{"trials":1085,"activeCount":99},[],{"trials":1087,"activeCount":99},[],{"intervention":435,"totalTrials":132,"cells":1089},{"EARLY_PHASE1":1090,"PHASE1":1092,"PHASE2":1094,"PHASE3":1100,"PHASE4":1102,"NA":1104},{"trials":1091,"activeCount":99},[],{"trials":1093,"activeCount":99},[],{"trials":1095,"activeCount":132,"soonestReadout":68},[1096],{"nctId":66,"briefTitle":67,"status":119,"phases":1097,"primaryCompletion":68,"completion":426,"start":427,"enrollment":428,"conditions":1098,"interventions":1099},[88],[430],[69,432,433,434,392,435,436],{"trials":1101,"activeCount":99},[],{"trials":1103,"activeCount":99},[],{"trials":1105,"activeCount":99},[],{"intervention":436,"totalTrials":132,"cells":1107},{"EARLY_PHASE1":1108,"PHASE1":1110,"PHASE2":1112,"PHASE3":1118,"PHASE4":1120,"NA":1122},{"trials":1109,"activeCount":99},[],{"trials":1111,"activeCount":99},[],{"trials":1113,"activeCount":132,"soonestReadout":68},[1114],{"nctId":66,"briefTitle":67,"status":119,"phases":1115,"primaryCompletion":68,"completion":426,"start":427,"enrollment":428,"conditions":1116,"interventions":1117},[88],[430],[69,432,433,434,392,435,436],{"trials":1119,"activeCount":99},[],{"trials":1121,"activeCount":99},[],{"trials":1123,"activeCount":99},[],{"intervention":1125,"totalTrials":132,"cells":1126},"Durvalumab with etoposide and Carboplatin\u002FCisplatin",{"EARLY_PHASE1":1127,"PHASE1":1129,"PHASE2":1131,"PHASE3":1144,"PHASE4":1146,"NA":1148},{"trials":1128,"activeCount":99},[],{"trials":1130,"activeCount":99},[],{"trials":1132,"activeCount":132,"soonestReadout":1137},[1133],{"nctId":1134,"briefTitle":1135,"status":119,"phases":1136,"primaryCompletion":1137,"completion":1138,"start":1139,"enrollment":1140,"conditions":1141,"interventions":1143},"NCT06393816","FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and Platinum",[88],"2028-09","2029-09","2024-06-13",80,[1142],"Large Cell Neuroendocrine Carcinoma of the Lung",[1125],{"trials":1145,"activeCount":99},[],{"trials":1147,"activeCount":99},[],{"trials":1149,"activeCount":99},[],{"intervention":1151,"totalTrials":132,"cells":1152},"Dostarlimab",{"EARLY_PHASE1":1153,"PHASE1":1155,"PHASE2":1157,"PHASE3":1172,"PHASE4":1174,"NA":1176},{"trials":1154,"activeCount":99},[],{"trials":1156,"activeCount":99},[],{"trials":1158,"activeCount":132,"soonestReadout":1163},[1159],{"nctId":1160,"briefTitle":1161,"status":119,"phases":1162,"primaryCompletion":1163,"completion":1164,"start":1165,"enrollment":1166,"conditions":1167,"interventions":1171},"NCT05855811","PREventing Second Cancers With DOSTARlimab",[88],"2028-07-26","2029-03-26","2023-07-26",400,[1168,1169,1170],"Recurrent Cancer","Primary Cancer","Second Cancer",[1151],{"trials":1173,"activeCount":99},[],{"trials":1175,"activeCount":99},[],{"trials":1177,"activeCount":99},[],{"intervention":1179,"totalTrials":132,"cells":1180},"Atezolizumab 1200 mg",{"EARLY_PHASE1":1181,"PHASE1":1183,"PHASE2":1185,"PHASE3":1198,"PHASE4":1200,"NA":1202},{"trials":1182,"activeCount":99},[],{"trials":1184,"activeCount":99},[],{"trials":1186,"activeCount":132,"soonestReadout":426},[1187],{"nctId":1188,"briefTitle":1189,"status":119,"phases":1190,"primaryCompletion":426,"completion":426,"start":1191,"enrollment":12,"conditions":1192,"interventions":1196},"NCT05152472","A Prospective, Randomized, Multicenter, Comparative Study of the Efficacy of Imatinib Resumption Combined With Atezolizumab Versus Imatinib Resumption Alone in Patients With Unresectable Advanced Gastrointestinal Stromal Tumors (GIST) After Failure of Standard Treatments",[88],"2022-01-14",[1193,1194,1195],"Unresectable Gastrointestinal Stromal Tumor (GIST)","Locally Advanced Gastrointestinal Stromal Tumor (GIST)","Metastatic Gastrointestinal Stromal Tumor",[1179,1197],"Imatinib 400 MG",{"trials":1199,"activeCount":99},[],{"trials":1201,"activeCount":99},[],{"trials":1203,"activeCount":99},[],{"intervention":1197,"totalTrials":132,"cells":1205},{"EARLY_PHASE1":1206,"PHASE1":1208,"PHASE2":1210,"PHASE3":1216,"PHASE4":1218,"NA":1220},{"trials":1207,"activeCount":99},[],{"trials":1209,"activeCount":99},[],{"trials":1211,"activeCount":132,"soonestReadout":426},[1212],{"nctId":1188,"briefTitle":1189,"status":119,"phases":1213,"primaryCompletion":426,"completion":426,"start":1191,"enrollment":12,"conditions":1214,"interventions":1215},[88],[1193,1194,1195],[1179,1197],{"trials":1217,"activeCount":99},[],{"trials":1219,"activeCount":99},[],{"trials":1221,"activeCount":99},[],{"intervention":679,"totalTrials":132,"cells":1223},{"EARLY_PHASE1":1224,"PHASE1":1226,"PHASE2":1228,"PHASE3":1234,"PHASE4":1236,"NA":1238},{"trials":1225,"activeCount":99},[],{"trials":1227,"activeCount":99},[],{"trials":1229,"activeCount":132,"soonestReadout":672},[1230],{"nctId":669,"briefTitle":670,"status":404,"phases":1231,"primaryCompletion":672,"completion":672,"start":673,"enrollment":674,"conditions":1232,"interventions":1233},[88],[676,677],[660,679],{"trials":1235,"activeCount":99},[],{"trials":1237,"activeCount":99},[],{"trials":1239,"activeCount":99},[],{"intervention":1241,"totalTrials":132,"cells":1242},"Trastuzumab + Paclitaxel",{"EARLY_PHASE1":1243,"PHASE1":1245,"PHASE2":1247,"PHASE3":1260,"PHASE4":1262,"NA":1264},{"trials":1244,"activeCount":99},[],{"trials":1246,"activeCount":99},[],{"trials":1248,"activeCount":132,"soonestReadout":506},[1249],{"nctId":1250,"briefTitle":1251,"status":404,"phases":1252,"primaryCompletion":506,"completion":1253,"start":1254,"enrollment":709,"conditions":1255,"interventions":1258},"NCT03571633","Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer",[88],"2027-09","2018-08-06",[1256,1257],"HER2-positive Breast Cancer","Operable Breast Cancer",[1241,1259],"Pegfilgrastim",{"trials":1261,"activeCount":99},[],{"trials":1263,"activeCount":99},[],{"trials":1265,"activeCount":99},[],{"intervention":1259,"totalTrials":95,"cells":1267},{"EARLY_PHASE1":1268,"PHASE1":1270,"PHASE2":1272,"PHASE3":1278,"PHASE4":1280,"NA":1282},{"trials":1269,"activeCount":99},[],{"trials":1271,"activeCount":99},[],{"trials":1273,"activeCount":132,"soonestReadout":506},[1274],{"nctId":1250,"briefTitle":1251,"status":404,"phases":1275,"primaryCompletion":506,"completion":1253,"start":1254,"enrollment":709,"conditions":1276,"interventions":1277},[88],[1256,1257],[1241,1259],{"trials":1279,"activeCount":99},[],{"trials":1281,"activeCount":99},[],{"trials":1283,"activeCount":99},[1284],{"nctId":1285,"briefTitle":1286,"status":546,"phases":1287,"primaryCompletion":1288,"completion":1289,"start":1290,"enrollment":1291,"conditions":1292,"interventions":1294},"NCT01541072","Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation",[91],"2014-06","2014-09","2012-02",34,[1293],"Non Hodgkin Lymphoma",[1259,1295],"Filgrastim",{"intervention":50,"totalTrials":34,"cells":1297},{"EARLY_PHASE1":1298,"PHASE1":1300,"PHASE2":1302,"PHASE3":1304,"PHASE4":1306,"NA":1308},{"trials":1299,"activeCount":99},[],{"trials":1301,"activeCount":99},[],{"trials":1303,"activeCount":99},[],{"trials":1305,"activeCount":99},[],{"trials":1307,"activeCount":99},[],{"trials":1309,"activeCount":95,"soonestReadout":49},[1310,1322,1332,1340],{"nctId":1311,"briefTitle":1312,"status":149,"phases":1313,"primaryCompletion":1314,"completion":1314,"start":1315,"enrollment":1316,"conditions":1317,"interventions":1321},"NCT05099068","Profiling Program of Cancer Patients With Sequential Tumor and Liquid Biopsies (PLANET)",[91],"2025-09-15","2021-11-16",500,[1318,1319,1320],"Advanced \u002F Metastic Solid Tumors","Glioblastoma","Chronic Leukemia Lymphocytic",[50],{"nctId":1323,"briefTitle":1324,"status":416,"phases":1325,"primaryCompletion":1326,"completion":1326,"start":1327,"enrollment":1328,"conditions":1329,"interventions":1331},"NCT03163732","Evaluation of the Added Value of a Large Molecular Profiling Panel Versus a Limited Molecular Profiling Panel in Advanced Solid Tumors.",[91],"2021-11-23","2017-06-29",341,[1330],"Advanced Solid Tumor",[50],{"nctId":57,"briefTitle":58,"status":119,"phases":1333,"primaryCompletion":59,"completion":1334,"start":1335,"enrollment":1336,"conditions":1337,"interventions":1339},[91],"2026-07","2013-02",10000,[1338],"Neoplasms",[50],{"nctId":47,"briefTitle":48,"status":404,"phases":1341,"primaryCompletion":49,"completion":1342,"start":1343,"enrollment":1344,"conditions":1345,"interventions":1347},[91],"2025-12-15","2018-02-15",376,[1346,26,28],"Soft Tissue Sarcoma",[50],{"intervention":84,"totalTrials":132,"cells":1349},{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1356,"PHASE4":1358,"NA":1360},{"trials":1351,"activeCount":99},[],{"trials":1353,"activeCount":99},[],{"trials":1355,"activeCount":99},[],{"trials":1357,"activeCount":99},[],{"trials":1359,"activeCount":99},[],{"trials":1361,"activeCount":132,"soonestReadout":83},[1362],{"nctId":81,"briefTitle":82,"status":119,"phases":1363,"primaryCompletion":83,"completion":83,"start":1364,"enrollment":1365,"conditions":1366,"interventions":1372},[91],"2020-03-03",168,[811,33,1367,1368,1369,1370,1371],"Ewing Sarcoma","Chondrosarcoma","Undifferentiated Pleomorphic Sarcoma","Leiomyosarcoma","Angiosarcoma",[84],{"intervention":1374,"totalTrials":132,"cells":1375},"Tumor samples (archival FFPE and optional de novo biopsy) and blood samples",{"EARLY_PHASE1":1376,"PHASE1":1378,"PHASE2":1380,"PHASE3":1382,"PHASE4":1384,"NA":1386},{"trials":1377,"activeCount":99},[],{"trials":1379,"activeCount":99},[],{"trials":1381,"activeCount":99},[],{"trials":1383,"activeCount":99},[],{"trials":1385,"activeCount":99},[],{"trials":1387,"activeCount":132,"soonestReadout":1392},[1388],{"nctId":1389,"briefTitle":1390,"status":119,"phases":1391,"primaryCompletion":1392,"completion":1392,"start":1393,"enrollment":1394,"conditions":1395,"interventions":1398},"NCT05380414","Profiling Program of Advanced\u002FMetastatic Pancreatic Cancer Patients",[91],"2027-09-01","2022-07-01",750,[1396,1397],"Metastatic Pancreatic Cancer","Advanced Pancreatic Cancer",[1374],{"intervention":1400,"totalTrials":95,"cells":1401},"aldesleukin",{"EARLY_PHASE1":1402,"PHASE1":1404,"PHASE2":1406,"PHASE3":1408,"PHASE4":1430,"NA":1432},{"trials":1403,"activeCount":99},[],{"trials":1405,"activeCount":99},[],{"trials":1407,"activeCount":99},[],{"trials":1409,"activeCount":99},[1410,1420],{"nctId":1411,"briefTitle":1412,"status":416,"phases":1413,"completion":1414,"enrollment":1415,"conditions":1416,"interventions":1418},"NCT00416871","Interleukin-2 and Interferon in Treating Patients With Metastatic Kidney Cancer",[89],"2006-02",220,[1417],"Kidney Cancer",[1400,1419],"recombinant interferon alfa",{"nctId":1421,"briefTitle":1422,"status":416,"phases":1423,"completion":1424,"enrollment":1425,"conditions":1426,"interventions":1427},"NCT00416429","Medroxyprogesterone or Interferon and\u002For Aldesleukin in Treating Patients With Metastatic Kidney Cancer",[89],"2005-02",456,[1417],[1400,1428,1429],"recombinant interferon alpha-2a","medroxyprogesterone",{"trials":1431,"activeCount":99},[],{"trials":1433,"activeCount":99},[],{"intervention":1435,"totalTrials":132,"cells":1436},"BRN01",{"EARLY_PHASE1":1437,"PHASE1":1439,"PHASE2":1441,"PHASE3":1443,"PHASE4":1455,"NA":1457},{"trials":1438,"activeCount":99},[],{"trials":1440,"activeCount":99},[],{"trials":1442,"activeCount":99},[],{"trials":1444,"activeCount":99},[1445],{"nctId":1446,"briefTitle":1447,"status":416,"phases":1448,"primaryCompletion":1449,"completion":1450,"start":1451,"enrollment":1452,"conditions":1453,"interventions":1454},"NCT01246427","Evaluation of Homeopathic Treatment for Hot Flashes in Non Metastatic Breast Cancer",[89],"2014-05","2014-11","2010-01",138,[15],[1435],{"trials":1456,"activeCount":99},[],{"trials":1458,"activeCount":99},[],{"intervention":1460,"totalTrials":132,"cells":1461},"Homeodent®",{"EARLY_PHASE1":1462,"PHASE1":1464,"PHASE2":1466,"PHASE3":1468,"PHASE4":1481,"NA":1483},{"trials":1463,"activeCount":99},[],{"trials":1465,"activeCount":99},[],{"trials":1467,"activeCount":99},[],{"trials":1469,"activeCount":99},[1470],{"nctId":1471,"briefTitle":1472,"status":546,"phases":1473,"primaryCompletion":1474,"completion":1475,"start":1476,"enrollment":1477,"conditions":1478,"interventions":1479},"NCT01066741","Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer",[89],"2011-02","2011-08","2009-05",78,[125,127],[1460,1480],"1.4% Sodium Bicarbonate solution",{"trials":1482,"activeCount":99},[],{"trials":1484,"activeCount":99},[],{"intervention":1480,"totalTrials":132,"cells":1486},{"EARLY_PHASE1":1487,"PHASE1":1489,"PHASE2":1491,"PHASE3":1493,"PHASE4":1499,"NA":1501},{"trials":1488,"activeCount":99},[],{"trials":1490,"activeCount":99},[],{"trials":1492,"activeCount":99},[],{"trials":1494,"activeCount":99},[1495],{"nctId":1471,"briefTitle":1472,"status":546,"phases":1496,"primaryCompletion":1474,"completion":1475,"start":1476,"enrollment":1477,"conditions":1497,"interventions":1498},[89],[125,127],[1460,1480],{"trials":1500,"activeCount":99},[],{"trials":1502,"activeCount":99},[],{"intervention":1504,"totalTrials":132,"cells":1505},"Imatinib maintenance",{"EARLY_PHASE1":1506,"PHASE1":1508,"PHASE2":1510,"PHASE3":1512,"PHASE4":1528,"NA":1530},{"trials":1507,"activeCount":99},[],{"trials":1509,"activeCount":99},[],{"trials":1511,"activeCount":99},[],{"trials":1513,"activeCount":99},[1514],{"nctId":1515,"briefTitle":1516,"status":416,"phases":1517,"primaryCompletion":1518,"completion":1518,"start":1519,"enrollment":1520,"conditions":1521,"interventions":1527},"NCT02260505","Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST)",[89],"2023-12","2014-12-24",136,[1522,1523,1524,1525,1526],"Gastrointestinal Stromal Tumors","Resected Gastrointestinal Stromal Tumors","Non-metastatic","High Risk of Recurrence","KIT Gene Mutation",[1504],{"trials":1529,"activeCount":99},[],{"trials":1531,"activeCount":99},[],{"intervention":1419,"totalTrials":132,"cells":1533},{"EARLY_PHASE1":1534,"PHASE1":1536,"PHASE2":1538,"PHASE3":1540,"PHASE4":1546,"NA":1548},{"trials":1535,"activeCount":99},[],{"trials":1537,"activeCount":99},[],{"trials":1539,"activeCount":99},[],{"trials":1541,"activeCount":99},[1542],{"nctId":1411,"briefTitle":1412,"status":416,"phases":1543,"completion":1414,"enrollment":1415,"conditions":1544,"interventions":1545},[89],[1417],[1400,1419],{"trials":1547,"activeCount":99},[],{"trials":1549,"activeCount":99},[],{"intervention":1551,"totalTrials":132,"cells":1552},"Cocculine®",{"EARLY_PHASE1":1553,"PHASE1":1555,"PHASE2":1557,"PHASE3":1559,"PHASE4":1570,"NA":1572},{"trials":1554,"activeCount":99},[],{"trials":1556,"activeCount":99},[],{"trials":1558,"activeCount":99},[],{"trials":1560,"activeCount":99},[1561],{"nctId":1562,"briefTitle":1563,"status":416,"phases":1564,"primaryCompletion":1565,"completion":1565,"start":1566,"enrollment":1567,"conditions":1568,"interventions":1569},"NCT00409071","Placebo-controlled Evaluation of Cocculine® Efficacy in the Management of Nausea After Chemotherapy in Breast Cancer.",[89],"2008-10","2005-09",431,[15],[1551],{"trials":1571,"activeCount":99},[],{"trials":1573,"activeCount":99},[],{"intervention":1428,"totalTrials":132,"cells":1575},{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1582,"PHASE4":1588,"NA":1590},{"trials":1577,"activeCount":99},[],{"trials":1579,"activeCount":99},[],{"trials":1581,"activeCount":99},[],{"trials":1583,"activeCount":99},[1584],{"nctId":1421,"briefTitle":1422,"status":416,"phases":1585,"completion":1424,"enrollment":1425,"conditions":1586,"interventions":1587},[89],[1417],[1400,1428,1429],{"trials":1589,"activeCount":99},[],{"trials":1591,"activeCount":99},[],{"intervention":1429,"totalTrials":132,"cells":1593},{"EARLY_PHASE1":1594,"PHASE1":1596,"PHASE2":1598,"PHASE3":1600,"PHASE4":1606,"NA":1608},{"trials":1595,"activeCount":99},[],{"trials":1597,"activeCount":99},[],{"trials":1599,"activeCount":99},[],{"trials":1601,"activeCount":99},[1602],{"nctId":1421,"briefTitle":1422,"status":416,"phases":1603,"completion":1424,"enrollment":1425,"conditions":1604,"interventions":1605},[89],[1417],[1400,1428,1429],{"trials":1607,"activeCount":99},[],{"trials":1609,"activeCount":99},[],{"intervention":1611,"totalTrials":132,"cells":1612},"interruption of Glivec®",{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1619,"PHASE4":1632,"NA":1634},{"trials":1614,"activeCount":99},[],{"trials":1616,"activeCount":99},[],{"trials":1618,"activeCount":99},[],{"trials":1620,"activeCount":99},[1621],{"nctId":1622,"briefTitle":1623,"status":416,"phases":1624,"primaryCompletion":1625,"completion":1626,"start":1627,"enrollment":1628,"conditions":1629,"interventions":1631},"NCT00367861","Prospective Multicentric Randomized Study of Glivec® in Advanced GIST Expressing C-kit: Interruption After 5 Years vs Maintenance",[89],"2012-04","2013-05","2002-05",564,[23,1630],"Gastro-intestinal Stromal Tumors (GIST)",[1611],{"trials":1633,"activeCount":99},[],{"trials":1635,"activeCount":99},[],{"intervention":1637,"totalTrials":132,"cells":1638},"AFATINIB",{"EARLY_PHASE1":1639,"PHASE1":1641,"PHASE2":1643,"PHASE3":1645,"PHASE4":1658,"NA":1660},{"trials":1640,"activeCount":99},[],{"trials":1642,"activeCount":99},[],{"trials":1644,"activeCount":99},[],{"trials":1646,"activeCount":99},[1647],{"nctId":1648,"briefTitle":1649,"status":416,"phases":1650,"primaryCompletion":1651,"completion":1652,"start":1653,"enrollment":1654,"conditions":1655,"interventions":1657},"NCT01427478","Evaluation of Afatinib in Maintenance Therapy in Squamous Cell Carcinoma of the Head and Neck",[89],"2020-11","2021-05","2011-09",134,[1656],"Head and Neck Squamous Cell Carcinoma",[1637],{"trials":1659,"activeCount":99},[],{"trials":1661,"activeCount":99},[],{"intervention":1663,"totalTrials":132,"cells":1664},"denosumab",{"EARLY_PHASE1":1665,"PHASE1":1667,"PHASE2":1669,"PHASE3":1671,"PHASE4":1681,"NA":1683},{"trials":1666,"activeCount":99},[],{"trials":1668,"activeCount":99},[],{"trials":1670,"activeCount":99},[],{"trials":1672,"activeCount":99},[1673],{"nctId":1674,"briefTitle":1675,"status":546,"phases":1676,"primaryCompletion":1677,"completion":1677,"start":1678,"enrollment":132,"conditions":1679,"interventions":1680},"NCT03408652","Efficacy and Safety of Systemic Treatments of Bone Metastases From Kidney Cancer in Patients Treated With Targeted Therapies",[89],"2020-06-22","2019-03-15",[30],[1663],{"trials":1682,"activeCount":99},[],{"trials":1684,"activeCount":99},[],{"intervention":1686,"totalTrials":132,"cells":1687},"Nivolumab and IPILIMUMAB",{"EARLY_PHASE1":1688,"PHASE1":1690,"PHASE2":1692,"PHASE3":1694,"PHASE4":1707,"NA":1709},{"trials":1689,"activeCount":99},[],{"trials":1691,"activeCount":99},[],{"trials":1693,"activeCount":99},[],{"trials":1695,"activeCount":99},[1696],{"nctId":1697,"briefTitle":1698,"status":149,"phases":1699,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1703,"conditions":1704,"interventions":1705},"NCT04741438","Efficacy of the Combination of Nivolumab and Ipilimumab as a Treatment in Patients With Sarcoma of Rare Subtype",[89],"2025-02","2025-08","2021-03-30",96,[23],[1686,1706],"Pazopanib Oral Tablet [Votrient]",{"trials":1708,"activeCount":99},[],{"trials":1710,"activeCount":99},[],{"intervention":1706,"totalTrials":132,"cells":1712},{"EARLY_PHASE1":1713,"PHASE1":1715,"PHASE2":1717,"PHASE3":1719,"PHASE4":1725,"NA":1727},{"trials":1714,"activeCount":99},[],{"trials":1716,"activeCount":99},[],{"trials":1718,"activeCount":99},[],{"trials":1720,"activeCount":99},[1721],{"nctId":1697,"briefTitle":1698,"status":149,"phases":1722,"primaryCompletion":1700,"completion":1701,"start":1702,"enrollment":1703,"conditions":1723,"interventions":1724},[89],[23],[1686,1706],{"trials":1726,"activeCount":99},[],{"trials":1728,"activeCount":99},[],{"intervention":1730,"totalTrials":132,"cells":1731},"cicaderma + simple hygiene rules",{"EARLY_PHASE1":1732,"PHASE1":1734,"PHASE2":1736,"PHASE3":1738,"PHASE4":1753,"NA":1755},{"trials":1733,"activeCount":99},[],{"trials":1735,"activeCount":99},[],{"trials":1737,"activeCount":99},[],{"trials":1739,"activeCount":99},[1740],{"nctId":1741,"briefTitle":1742,"status":149,"phases":1743,"primaryCompletion":1744,"completion":1745,"start":1746,"enrollment":1747,"conditions":1748,"interventions":1752},"NCT04300829","Cicaderma Efficacy vs Standard Care of Sites in Preventing Radiodermatitis in Non-metastatic Breast Cancer Patients",[89],"2022-09-09","2022-10-09","2020-06-06",248,[1749,1750,1751],"Breast Adenocarcinoma","Radiation Dermatitis","Radiation Toxicity",[1730],{"trials":1754,"activeCount":99},[],{"trials":1756,"activeCount":99},[],{"intervention":1758,"totalTrials":132,"cells":1759},"Interleukin-2",{"EARLY_PHASE1":1760,"PHASE1":1762,"PHASE2":1764,"PHASE3":1766,"PHASE4":1777,"NA":1779},{"trials":1761,"activeCount":99},[],{"trials":1763,"activeCount":99},[],{"trials":1765,"activeCount":99},[],{"trials":1767,"activeCount":99},[1768],{"nctId":1769,"briefTitle":1770,"status":416,"phases":1771,"completion":1424,"start":1772,"enrollment":1425,"conditions":1773,"interventions":1774},"NCT00291369","Cytokines in Patients With Metastatic Renal Cell Carcinoma of Intermediate Prognosis",[89],"1999-12",[30],[1758,1775,1776],"Interferon alfa","medroxyprogesterone acetate",{"trials":1778,"activeCount":99},[],{"trials":1780,"activeCount":99},[],{"intervention":1775,"totalTrials":132,"cells":1782},{"EARLY_PHASE1":1783,"PHASE1":1785,"PHASE2":1787,"PHASE3":1789,"PHASE4":1795,"NA":1797},{"trials":1784,"activeCount":99},[],{"trials":1786,"activeCount":99},[],{"trials":1788,"activeCount":99},[],{"trials":1790,"activeCount":99},[1791],{"nctId":1769,"briefTitle":1770,"status":416,"phases":1792,"completion":1424,"start":1772,"enrollment":1425,"conditions":1793,"interventions":1794},[89],[30],[1758,1775,1776],{"trials":1796,"activeCount":99},[],{"trials":1798,"activeCount":99},[],{"intervention":1776,"totalTrials":132,"cells":1800},{"EARLY_PHASE1":1801,"PHASE1":1803,"PHASE2":1805,"PHASE3":1807,"PHASE4":1813,"NA":1815},{"trials":1802,"activeCount":99},[],{"trials":1804,"activeCount":99},[],{"trials":1806,"activeCount":99},[],{"trials":1808,"activeCount":99},[1809],{"nctId":1769,"briefTitle":1770,"status":416,"phases":1810,"completion":1424,"start":1772,"enrollment":1425,"conditions":1811,"interventions":1812},[89],[30],[1758,1775,1776],{"trials":1814,"activeCount":99},[],{"trials":1816,"activeCount":99},[],{"intervention":1818,"totalTrials":393,"cells":1819},"Bevacizumab",{"EARLY_PHASE1":1820,"PHASE1":1822,"PHASE2":1824,"PHASE3":1860,"PHASE4":1862,"NA":1864},{"trials":1821,"activeCount":99},[],{"trials":1823,"activeCount":99},[],{"trials":1825,"activeCount":99},[1826,1837,1849],{"nctId":1827,"briefTitle":1828,"status":416,"phases":1829,"primaryCompletion":1290,"completion":1290,"start":1830,"enrollment":1831,"conditions":1832,"interventions":1833},"NCT00619268","Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma",[88],"2008-02",160,[30],[1834,1818,1835,1836],"Temsirolimus","Sunitinib","Interferon alpha-2a",{"nctId":1838,"briefTitle":1839,"status":107,"phases":1840,"primaryCompletion":1841,"completion":1841,"start":1842,"enrollment":99,"conditions":1843,"interventions":1847},"NCT07146919","AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer",[87,88],"2030-10-15","2025-10-15",[1844,1845,1846],"Endometrial Carcinoma","Ovarian Cancer","Cervix Cancer",[1848,1818],"Bemarituzumab",{"nctId":1850,"briefTitle":1851,"status":416,"phases":1852,"primaryCompletion":1853,"completion":1853,"start":1854,"enrollment":1855,"conditions":1856,"interventions":1858},"NCT03818061","Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck",[88],"2025-01-15","2019-03-26",33,[1857],"Head and Neck Neoplasms",[1859,1818],"Atezolizumab",{"trials":1861,"activeCount":99},[],{"trials":1863,"activeCount":99},[],{"trials":1865,"activeCount":99},[],{"intervention":1835,"totalTrials":95,"cells":1867},{"EARLY_PHASE1":1868,"PHASE1":1870,"PHASE2":1883,"PHASE3":1889,"PHASE4":1891,"NA":1893},{"trials":1869,"activeCount":99},[],{"trials":1871,"activeCount":99},[1872],{"nctId":1873,"briefTitle":1874,"status":416,"phases":1875,"primaryCompletion":1876,"completion":1877,"start":419,"enrollment":1878,"conditions":1879,"interventions":1881},"NCT01308034","Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy",[87],"2016-05","2016-09-21",25,[1880],"Non GIST Sarcomas",[1882],"sunitinib",{"trials":1884,"activeCount":99},[1885],{"nctId":1827,"briefTitle":1828,"status":416,"phases":1886,"primaryCompletion":1290,"completion":1290,"start":1830,"enrollment":1831,"conditions":1887,"interventions":1888},[88],[30],[1834,1818,1835,1836],{"trials":1890,"activeCount":99},[],{"trials":1892,"activeCount":99},[],{"trials":1894,"activeCount":99},[],{"intervention":1859,"totalTrials":95,"cells":1896},{"EARLY_PHASE1":1897,"PHASE1":1899,"PHASE2":1901,"PHASE3":1918,"PHASE4":1920,"NA":1922},{"trials":1898,"activeCount":99},[],{"trials":1900,"activeCount":99},[],{"trials":1902,"activeCount":99},[1903,1914],{"nctId":1904,"briefTitle":1905,"status":416,"phases":1906,"primaryCompletion":1907,"completion":1908,"start":1909,"enrollment":1910,"conditions":1911,"interventions":1912},"NCT04216953","MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and\u002For Metastatic Soft Tissue Sarcoma",[87,88],"2024-12-01","2025-03-17","2020-02-12",229,[970],[1913,1859],"Cobimetinib",{"nctId":1850,"briefTitle":1851,"status":416,"phases":1915,"primaryCompletion":1853,"completion":1853,"start":1854,"enrollment":1855,"conditions":1916,"interventions":1917},[88],[1857],[1859,1818],{"trials":1919,"activeCount":99},[],{"trials":1921,"activeCount":99},[],{"trials":1923,"activeCount":99},[],{"intervention":158,"totalTrials":95,"cells":1925},{"EARLY_PHASE1":1926,"PHASE1":1928,"PHASE2":1943,"PHASE3":1949,"PHASE4":1951,"NA":1953},{"trials":1927,"activeCount":99},[],{"trials":1929,"activeCount":99},[1930],{"nctId":1931,"briefTitle":1932,"status":416,"phases":1933,"primaryCompletion":1934,"completion":1935,"start":1936,"enrollment":1937,"conditions":1938,"interventions":1941},"NCT02977156","Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic \u002F Advanced Solid Tumors.",[87],"2022-04-13","2022-06-06","2017-01-03",22,[1939,1940],"Metastatic Tumor","Advanced Tumor",[1942,158],"Pexa-Vec",{"trials":1944,"activeCount":99},[1945],{"nctId":147,"briefTitle":148,"status":149,"phases":1946,"primaryCompletion":151,"completion":152,"start":153,"enrollment":154,"conditions":1947,"interventions":1948},[88],[15,156],[138,158,159],{"trials":1950,"activeCount":99},[],{"trials":1952,"activeCount":99},[],{"trials":1954,"activeCount":99},[],{"intervention":1956,"totalTrials":132,"cells":1957},"Autophagy inhibitor",{"EARLY_PHASE1":1958,"PHASE1":1960,"PHASE2":1962,"PHASE3":1977,"PHASE4":1979,"NA":1981},{"trials":1959,"activeCount":99},[],{"trials":1961,"activeCount":99},[],{"trials":1963,"activeCount":99},[1964],{"nctId":1965,"briefTitle":1966,"status":416,"phases":1967,"primaryCompletion":1968,"completion":1969,"start":1970,"enrollment":9,"conditions":1971,"interventions":1974},"NCT04333914","Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection",[88],"2021-07-06","2021-12-31","2020-04-15",[1972,1973],"SARS-CoV-2 (COVID-19) Infection","Advanced or Metastatic Hematological or Solid Tumor",[1956,1975,1976],"Avdoralimab","Monalizumab",{"trials":1978,"activeCount":99},[],{"trials":1980,"activeCount":99},[],{"trials":1982,"activeCount":99},[],{"intervention":1975,"totalTrials":132,"cells":1984},{"EARLY_PHASE1":1985,"PHASE1":1987,"PHASE2":1989,"PHASE3":1995,"PHASE4":1997,"NA":1999},{"trials":1986,"activeCount":99},[],{"trials":1988,"activeCount":99},[],{"trials":1990,"activeCount":99},[1991],{"nctId":1965,"briefTitle":1966,"status":416,"phases":1992,"primaryCompletion":1968,"completion":1969,"start":1970,"enrollment":9,"conditions":1993,"interventions":1994},[88],[1972,1973],[1956,1975,1976],{"trials":1996,"activeCount":99},[],{"trials":1998,"activeCount":99},[],{"trials":2000,"activeCount":99},[],{"intervention":1976,"totalTrials":132,"cells":2002},{"EARLY_PHASE1":2003,"PHASE1":2005,"PHASE2":2007,"PHASE3":2013,"PHASE4":2015,"NA":2017},{"trials":2004,"activeCount":99},[],{"trials":2006,"activeCount":99},[],{"trials":2008,"activeCount":99},[2009],{"nctId":1965,"briefTitle":1966,"status":416,"phases":2010,"primaryCompletion":1968,"completion":1969,"start":1970,"enrollment":9,"conditions":2011,"interventions":2012},[88],[1972,1973],[1956,1975,1976],{"trials":2014,"activeCount":99},[],{"trials":2016,"activeCount":99},[],{"trials":2018,"activeCount":99},[],{"intervention":2020,"totalTrials":132,"cells":2021},"Durvalumab with Carboplatin\u002FPaclitaxel",{"EARLY_PHASE1":2022,"PHASE1":2024,"PHASE2":2026,"PHASE3":2039,"PHASE4":2041,"NA":2043},{"trials":2023,"activeCount":99},[],{"trials":2025,"activeCount":99},[],{"trials":2027,"activeCount":99},[2028],{"nctId":2029,"briefTitle":2030,"status":416,"phases":2031,"primaryCompletion":2032,"completion":2033,"start":2034,"enrollment":2035,"conditions":2036,"interventions":2038},"NCT03723967","FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin\u002FPaclitaxel",[88],"2020-05-16","2024-03-09","2019-05-16",104,[2037],"Squamous Cell Carcinoma of the Head and Neck",[2020],{"trials":2040,"activeCount":99},[],{"trials":2042,"activeCount":99},[],{"trials":2044,"activeCount":99},[],{"intervention":2046,"totalTrials":132,"cells":2047},"Velbe-Bleomycin-Cisplatin",{"EARLY_PHASE1":2048,"PHASE1":2050,"PHASE2":2052,"PHASE3":2065,"PHASE4":2067,"NA":2069},{"trials":2049,"activeCount":99},[],{"trials":2051,"activeCount":99},[],{"trials":2053,"activeCount":99},[2054],{"nctId":2055,"briefTitle":2056,"status":416,"phases":2057,"primaryCompletion":2058,"completion":2058,"start":2059,"enrollment":2060,"conditions":2061,"interventions":2063},"NCT02104986","A Multicenter Study to Evaluate a Risk-adapted Strategy for Treatment of Extra Cranial Non Seminomateous Malignant Germ Cell Tumour in Children and Adolescent",[88],"2021-10-14","2014-05-12",117,[2062],"Extra Cranial Non Seminomateous Malignant Germ Cell Tumour",[2046,2064],"Vepeside-ifosfamide-Cisplatin",{"trials":2066,"activeCount":99},[],{"trials":2068,"activeCount":99},[],{"trials":2070,"activeCount":99},[],{"intervention":2064,"totalTrials":132,"cells":2072},{"EARLY_PHASE1":2073,"PHASE1":2075,"PHASE2":2077,"PHASE3":2083,"PHASE4":2085,"NA":2087},{"trials":2074,"activeCount":99},[],{"trials":2076,"activeCount":99},[],{"trials":2078,"activeCount":99},[2079],{"nctId":2055,"briefTitle":2056,"status":416,"phases":2080,"primaryCompletion":2058,"completion":2058,"start":2059,"enrollment":2060,"conditions":2081,"interventions":2082},[88],[2062],[2046,2064],{"trials":2084,"activeCount":99},[],{"trials":2086,"activeCount":99},[],{"trials":2088,"activeCount":99},[],{"intervention":2090,"totalTrials":132,"cells":2091},"Continuous pazopanib",{"EARLY_PHASE1":2092,"PHASE1":2094,"PHASE2":2096,"PHASE3":2108,"PHASE4":2110,"NA":2112},{"trials":2093,"activeCount":99},[],{"trials":2095,"activeCount":99},[],{"trials":2097,"activeCount":99},[2098],{"nctId":2099,"briefTitle":2100,"status":416,"phases":2101,"primaryCompletion":2102,"completion":2102,"start":2103,"enrollment":1365,"conditions":2104,"interventions":2106},"NCT01813136","Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma",[88],"2019-01","2013-03",[2105],"Thyroid Carcinoma",[2090,2107],"Intermittent pazopanib",{"trials":2109,"activeCount":99},[],{"trials":2111,"activeCount":99},[],{"trials":2113,"activeCount":99},[],{"intervention":2107,"totalTrials":132,"cells":2115},{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2126,"PHASE4":2128,"NA":2130},{"trials":2117,"activeCount":99},[],{"trials":2119,"activeCount":99},[],{"trials":2121,"activeCount":99},[2122],{"nctId":2099,"briefTitle":2100,"status":416,"phases":2123,"primaryCompletion":2102,"completion":2102,"start":2103,"enrollment":1365,"conditions":2124,"interventions":2125},[88],[2105],[2090,2107],{"trials":2127,"activeCount":99},[],{"trials":2129,"activeCount":99},[],{"trials":2131,"activeCount":99},[],{"intervention":113,"totalTrials":132,"cells":2133},{"EARLY_PHASE1":2134,"PHASE1":2136,"PHASE2":2138,"PHASE3":2144,"PHASE4":2146,"NA":2148},{"trials":2135,"activeCount":99},[],{"trials":2137,"activeCount":99},[],{"trials":2139,"activeCount":99},[2140],{"nctId":105,"briefTitle":106,"status":107,"phases":2141,"primaryCompletion":109,"completion":109,"start":109,"enrollment":99,"conditions":2142,"interventions":2143},[88],[111],[94,113],{"trials":2145,"activeCount":99},[],{"trials":2147,"activeCount":99},[],{"trials":2149,"activeCount":99},[],{"intervention":2151,"totalTrials":132,"cells":2152},"Abemaciclib",{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2169,"PHASE4":2171,"NA":2173},{"trials":2154,"activeCount":99},[],{"trials":2156,"activeCount":99},[],{"trials":2158,"activeCount":99},[2159],{"nctId":2160,"briefTitle":2161,"status":416,"phases":2162,"primaryCompletion":2163,"completion":2164,"start":2165,"enrollment":1878,"conditions":2166,"interventions":2168},"NCT03356223","Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced\u002FMetastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and\u002For an Amplification of CCND1 and\u002For of CDK6",[88],"2022-11-05","2022-12-05","2018-02-05",[2167,26,28],"Head and Neck Cancer",[2151],{"trials":2170,"activeCount":99},[],{"trials":2172,"activeCount":99},[],{"trials":2174,"activeCount":99},[],{"intervention":2176,"totalTrials":132,"cells":2177},"Niraparib",{"EARLY_PHASE1":2178,"PHASE1":2180,"PHASE2":2182,"PHASE3":2192,"PHASE4":2194,"NA":2196},{"trials":2179,"activeCount":99},[],{"trials":2181,"activeCount":99},[],{"trials":2183,"activeCount":99},[2184],{"nctId":2185,"briefTitle":2186,"status":546,"phases":2187,"primaryCompletion":2188,"completion":2188,"start":2189,"enrollment":95,"conditions":2190,"interventions":2191},"NCT05442749","Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer",[88],"2024-08-30","2022-10-28",[1396],[2176],{"trials":2193,"activeCount":99},[],{"trials":2195,"activeCount":99},[],{"trials":2197,"activeCount":99},[],{"intervention":2199,"totalTrials":132,"cells":2200},"AZD2014",{"EARLY_PHASE1":2201,"PHASE1":2203,"PHASE2":2205,"PHASE3":2219,"PHASE4":2221,"NA":2223},{"trials":2202,"activeCount":99},[],{"trials":2204,"activeCount":99},[],{"trials":2206,"activeCount":99},[2207],{"nctId":2208,"briefTitle":2209,"status":149,"phases":2210,"primaryCompletion":2211,"completion":2212,"start":2213,"enrollment":751,"conditions":2214,"interventions":2217},"NCT02730923","Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1\u002FmTORC2 Inhibitor and Anastrozole (VICTORIA)",[87,88],"2019-11","2024-12","2016-04",[1844,2215,2216],"Metastatic Carcinoma","Hormone Receptor Positive Tumor",[2199,2218],"Anastrozole",{"trials":2220,"activeCount":99},[],{"trials":2222,"activeCount":99},[],{"trials":2224,"activeCount":99},[],{"intervention":2218,"totalTrials":132,"cells":2226},{"EARLY_PHASE1":2227,"PHASE1":2229,"PHASE2":2231,"PHASE3":2237,"PHASE4":2239,"NA":2241},{"trials":2228,"activeCount":99},[],{"trials":2230,"activeCount":99},[],{"trials":2232,"activeCount":99},[2233],{"nctId":2208,"briefTitle":2209,"status":149,"phases":2234,"primaryCompletion":2211,"completion":2212,"start":2213,"enrollment":751,"conditions":2235,"interventions":2236},[87,88],[1844,2215,2216],[2199,2218],{"trials":2238,"activeCount":99},[],{"trials":2240,"activeCount":99},[],{"trials":2242,"activeCount":99},[],{"intervention":1834,"totalTrials":132,"cells":2244},{"EARLY_PHASE1":2245,"PHASE1":2247,"PHASE2":2249,"PHASE3":2255,"PHASE4":2257,"NA":2259},{"trials":2246,"activeCount":99},[],{"trials":2248,"activeCount":99},[],{"trials":2250,"activeCount":99},[2251],{"nctId":1827,"briefTitle":1828,"status":416,"phases":2252,"primaryCompletion":1290,"completion":1290,"start":1830,"enrollment":1831,"conditions":2253,"interventions":2254},[88],[30],[1834,1818,1835,1836],{"trials":2256,"activeCount":99},[],{"trials":2258,"activeCount":99},[],{"trials":2260,"activeCount":99},[],{"intervention":1836,"totalTrials":132,"cells":2262},{"EARLY_PHASE1":2263,"PHASE1":2265,"PHASE2":2267,"PHASE3":2273,"PHASE4":2275,"NA":2277},{"trials":2264,"activeCount":99},[],{"trials":2266,"activeCount":99},[],{"trials":2268,"activeCount":99},[2269],{"nctId":1827,"briefTitle":1828,"status":416,"phases":2270,"primaryCompletion":1290,"completion":1290,"start":1830,"enrollment":1831,"conditions":2271,"interventions":2272},[88],[30],[1834,1818,1835,1836],{"trials":2274,"activeCount":99},[],{"trials":2276,"activeCount":99},[],{"trials":2278,"activeCount":99},[],{"intervention":2280,"totalTrials":132,"cells":2281},"Firmagon",{"EARLY_PHASE1":2282,"PHASE1":2284,"PHASE2":2286,"PHASE3":2298,"PHASE4":2300,"NA":2302},{"trials":2283,"activeCount":99},[],{"trials":2285,"activeCount":99},[],{"trials":2287,"activeCount":99},[2288],{"nctId":2289,"briefTitle":2290,"status":416,"phases":2291,"primaryCompletion":2292,"completion":2293,"start":2294,"enrollment":674,"conditions":2295,"interventions":2297},"NCT04391556","Interest of PET-PSMA Imaging Potentialised by Androgen Blockade in Localized Prostatic Adenocarcinoma",[88],"2023-05-02","2024-04-03","2020-09-14",[2296],"Prostate Adenocarcinoma",[2280],{"trials":2299,"activeCount":99},[],{"trials":2301,"activeCount":99},[],{"trials":2303,"activeCount":99},[],{"intervention":2305,"totalTrials":132,"cells":2306},"Carboplatin",{"EARLY_PHASE1":2307,"PHASE1":2309,"PHASE2":2311,"PHASE3":2324,"PHASE4":2326,"NA":2328},{"trials":2308,"activeCount":99},[],{"trials":2310,"activeCount":99},[],{"trials":2312,"activeCount":99},[2313],{"nctId":2314,"briefTitle":2315,"status":416,"phases":2316,"primaryCompletion":2317,"completion":1451,"start":2318,"enrollment":2319,"conditions":2320,"interventions":2322},"NCT00973882","Carboplatin-Etoposide Combination in Hormone-Resistant Prostate Cancers",[88],"2009-07","2005-04",60,[2321],"Prostate Cancer",[2305,2323],"Etoposide",{"trials":2325,"activeCount":99},[],{"trials":2327,"activeCount":99},[],{"trials":2329,"activeCount":99},[],{"intervention":2323,"totalTrials":132,"cells":2331},{"EARLY_PHASE1":2332,"PHASE1":2334,"PHASE2":2336,"PHASE3":2342,"PHASE4":2344,"NA":2346},{"trials":2333,"activeCount":99},[],{"trials":2335,"activeCount":99},[],{"trials":2337,"activeCount":99},[2338],{"nctId":2314,"briefTitle":2315,"status":416,"phases":2339,"primaryCompletion":2317,"completion":1451,"start":2318,"enrollment":2319,"conditions":2340,"interventions":2341},[88],[2321],[2305,2323],{"trials":2343,"activeCount":99},[],{"trials":2345,"activeCount":99},[],{"trials":2347,"activeCount":99},[],{"intervention":2349,"totalTrials":132,"cells":2350},"interleukin 7",{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2366,"PHASE4":2368,"NA":2370},{"trials":2352,"activeCount":99},[],{"trials":2354,"activeCount":99},[],{"trials":2356,"activeCount":99},[2357],{"nctId":2358,"briefTitle":2359,"status":416,"phases":2360,"primaryCompletion":2361,"completion":1288,"start":2362,"enrollment":551,"conditions":2363,"interventions":2365},"NCT01368107","Study Evaluating Impact of IL-7 on CD4 Lymphopenia, Risks of Severe Haematological Toxicity and Tumor Progression in Metastatic Breast Cancer Patients",[88],"2013-09","2011-06",[2364],"Metastatic Breast Cancer",[2349,2349,2349],{"trials":2367,"activeCount":99},[],{"trials":2369,"activeCount":99},[],{"trials":2371,"activeCount":99},[],{"intervention":2373,"totalTrials":132,"cells":2374},"LBH589",{"EARLY_PHASE1":2375,"PHASE1":2377,"PHASE2":2379,"PHASE3":2389,"PHASE4":2391,"NA":2393},{"trials":2376,"activeCount":99},[],{"trials":2378,"activeCount":99},[],{"trials":2380,"activeCount":99},[2381],{"nctId":2382,"briefTitle":2383,"status":416,"phases":2384,"primaryCompletion":2385,"completion":2386,"start":1451,"enrollment":11,"conditions":2387,"interventions":2388},"NCT01136499","Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure",[88],"2012-01","2013-01",[1346],[2373],{"trials":2390,"activeCount":99},[],{"trials":2392,"activeCount":99},[],{"trials":2394,"activeCount":99},[],{"intervention":2396,"totalTrials":132,"cells":2397},"Cyclophosphamide 50mg",{"EARLY_PHASE1":2398,"PHASE1":2400,"PHASE2":2402,"PHASE3":2414,"PHASE4":2416,"NA":2418},{"trials":2399,"activeCount":99},[],{"trials":2401,"activeCount":99},[],{"trials":2403,"activeCount":99},[2404],{"nctId":2405,"briefTitle":2406,"status":416,"phases":2407,"primaryCompletion":2408,"completion":2409,"start":2410,"enrollment":809,"conditions":2411,"interventions":2412},"NCT03139851","Evaluation of Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated With Metronomic Cyclophosphamide",[88],"2018-09-26","2019-09-18","2017-06-27",[2364],[2396,2413],"Pembrolizumab 100 MG in 4 ML",{"trials":2415,"activeCount":99},[],{"trials":2417,"activeCount":99},[],{"trials":2419,"activeCount":99},[],{"intervention":2413,"totalTrials":132,"cells":2421},{"EARLY_PHASE1":2422,"PHASE1":2424,"PHASE2":2426,"PHASE3":2432,"PHASE4":2434,"NA":2436},{"trials":2423,"activeCount":99},[],{"trials":2425,"activeCount":99},[],{"trials":2427,"activeCount":99},[2428],{"nctId":2405,"briefTitle":2406,"status":416,"phases":2429,"primaryCompletion":2408,"completion":2409,"start":2410,"enrollment":809,"conditions":2430,"interventions":2431},[88],[2364],[2396,2413],{"trials":2433,"activeCount":99},[],{"trials":2435,"activeCount":99},[],{"trials":2437,"activeCount":99},[],{"intervention":1913,"totalTrials":132,"cells":2439},{"EARLY_PHASE1":2440,"PHASE1":2442,"PHASE2":2444,"PHASE3":2450,"PHASE4":2452,"NA":2454},{"trials":2441,"activeCount":99},[],{"trials":2443,"activeCount":99},[],{"trials":2445,"activeCount":99},[2446],{"nctId":1904,"briefTitle":1905,"status":416,"phases":2447,"primaryCompletion":1907,"completion":1908,"start":1909,"enrollment":1910,"conditions":2448,"interventions":2449},[87,88],[970],[1913,1859],{"trials":2451,"activeCount":99},[],{"trials":2453,"activeCount":99},[],{"trials":2455,"activeCount":99},[],{"intervention":2457,"totalTrials":132,"cells":2458},"AGuIX",{"EARLY_PHASE1":2459,"PHASE1":2461,"PHASE2":2463,"PHASE3":2474,"PHASE4":2476,"NA":2478},{"trials":2460,"activeCount":99},[],{"trials":2462,"activeCount":99},[],{"trials":2464,"activeCount":99},[2465],{"nctId":2466,"briefTitle":2467,"status":546,"phases":2468,"primaryCompletion":2469,"completion":2469,"start":2470,"enrollment":132,"conditions":2471,"interventions":2473},"NCT04094077","Evaluating AGuIX® Nanoparticles in Combination With Stereotactic Radiation for Brain Metastases",[88],"2021-02-24","2020-01-17",[2472],"Brain Metastases",[2457],{"trials":2475,"activeCount":99},[],{"trials":2477,"activeCount":99},[],{"trials":2479,"activeCount":99},[],{"intervention":2481,"totalTrials":132,"cells":2482},"Lidocaine",{"EARLY_PHASE1":2483,"PHASE1":2485,"PHASE2":2487,"PHASE3":2499,"PHASE4":2501,"NA":2503},{"trials":2484,"activeCount":99},[],{"trials":2486,"activeCount":99},[],{"trials":2488,"activeCount":99},[2489],{"nctId":2490,"briefTitle":2491,"status":416,"phases":2492,"primaryCompletion":2493,"completion":2493,"start":419,"enrollment":2494,"conditions":2495,"interventions":2498},"NCT01314300","Lidocaine 5% Plasters (Versatis® 5%) in Pediatric Neuropathic Pains and Vasoocclusive Sickle Cell Crisis Pains",[88],"2014-07",39,[2496,2497],"Neuropathic Pains","Vasoocclusive Sickle Cell Crises Pains",[2481],{"trials":2500,"activeCount":99},[],{"trials":2502,"activeCount":99},[],{"trials":2504,"activeCount":99},[],{"intervention":2506,"totalTrials":132,"cells":2507},"Tasigna",{"EARLY_PHASE1":2508,"PHASE1":2510,"PHASE2":2512,"PHASE3":2523,"PHASE4":2525,"NA":2527},{"trials":2509,"activeCount":99},[],{"trials":2511,"activeCount":99},[],{"trials":2513,"activeCount":99},[2514],{"nctId":2515,"briefTitle":2516,"status":416,"phases":2517,"primaryCompletion":2518,"completion":2518,"start":2519,"enrollment":508,"conditions":2520,"interventions":2522},"NCT01261429","Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis\u002F Tenosynovial Giant Cell Tumour (PVNS\u002FTGCT)",[88],"2013-04","2010-12",[2521],"Pigmented Villonodular Synovitis",[2506],{"trials":2524,"activeCount":99},[],{"trials":2526,"activeCount":99},[],{"trials":2528,"activeCount":99},[],{"intervention":159,"totalTrials":132,"cells":2530},{"EARLY_PHASE1":2531,"PHASE1":2533,"PHASE2":2535,"PHASE3":2541,"PHASE4":2543,"NA":2545},{"trials":2532,"activeCount":99},[],{"trials":2534,"activeCount":99},[],{"trials":2536,"activeCount":99},[2537],{"nctId":147,"briefTitle":148,"status":149,"phases":2538,"primaryCompletion":151,"completion":152,"start":153,"enrollment":154,"conditions":2539,"interventions":2540},[88],[15,156],[138,158,159],{"trials":2542,"activeCount":99},[],{"trials":2544,"activeCount":99},[],{"trials":2546,"activeCount":99},[],{"intervention":2548,"totalTrials":132,"cells":2549},"Thiotepa",{"EARLY_PHASE1":2550,"PHASE1":2552,"PHASE2":2554,"PHASE3":2564,"PHASE4":2566,"NA":2568},{"trials":2551,"activeCount":99},[],{"trials":2553,"activeCount":99},[],{"trials":2555,"activeCount":99},[2556],{"nctId":2557,"briefTitle":2558,"status":416,"phases":2559,"primaryCompletion":2560,"completion":2560,"start":2317,"enrollment":2561,"conditions":2562,"interventions":2563},"NCT00978471","Adjuvant High-Dose Thiotepa and Stem Cell Rescue Associated With Conventional Chemotherapy in Relapsed Osteosarcoma",[88],"2018-10-29",44,[33],[2548],{"trials":2565,"activeCount":99},[],{"trials":2567,"activeCount":99},[],{"trials":2569,"activeCount":99},[],{"intervention":556,"totalTrials":132,"cells":2571},{"EARLY_PHASE1":2572,"PHASE1":2574,"PHASE2":2576,"PHASE3":2582,"PHASE4":2584,"NA":2586},{"trials":2573,"activeCount":99},[],{"trials":2575,"activeCount":99},[],{"trials":2577,"activeCount":99},[2578],{"nctId":544,"briefTitle":545,"status":546,"phases":2579,"primaryCompletion":548,"completion":549,"start":550,"enrollment":551,"conditions":2580,"interventions":2581},[87,88],[553,554],[556,521],{"trials":2583,"activeCount":99},[],{"trials":2585,"activeCount":99},[],{"trials":2587,"activeCount":99},[],{"intervention":2589,"totalTrials":132,"cells":2590},"BeEAM",{"EARLY_PHASE1":2591,"PHASE1":2593,"PHASE2":2595,"PHASE3":2607,"PHASE4":2609,"NA":2611},{"trials":2592,"activeCount":99},[],{"trials":2594,"activeCount":99},[],{"trials":2596,"activeCount":99},[2597],{"nctId":2598,"briefTitle":2599,"status":546,"phases":2600,"primaryCompletion":2601,"completion":2601,"start":2602,"enrollment":2603,"conditions":2604,"interventions":2606},"NCT02008006","BENdamustine at Elevated Dose for Relapsed Follicular Lymphoma in Intensification Therapy and Transplantation (BENEFIT)",[88],"2018-07-12","2014-07-09",21,[2605],"Follicular Lymphoma",[2589],{"trials":2608,"activeCount":99},[],{"trials":2610,"activeCount":99},[],{"trials":2612,"activeCount":99},[],{"intervention":2614,"totalTrials":132,"cells":2615},"BKM120",{"EARLY_PHASE1":2616,"PHASE1":2618,"PHASE2":2620,"PHASE3":2634,"PHASE4":2636,"NA":2638},{"trials":2617,"activeCount":99},[],{"trials":2619,"activeCount":99},[],{"trials":2621,"activeCount":99},[2622],{"nctId":2623,"briefTitle":2624,"status":416,"phases":2625,"primaryCompletion":2626,"completion":2627,"start":2386,"enrollment":2628,"conditions":2629,"interventions":2633},"NCT01737450","Activity and Safety Study of BKM120 in Monotherapy in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive",[88],"2018-09","2019-03",58,[1857,2630,2631,2632],"Neoplasm Metastasis","Recurrent Disease","Progressive Disease",[2614],{"trials":2635,"activeCount":99},[],{"trials":2637,"activeCount":99},[],{"trials":2639,"activeCount":99},[],{"intervention":1848,"totalTrials":132,"cells":2641},{"EARLY_PHASE1":2642,"PHASE1":2644,"PHASE2":2646,"PHASE3":2652,"PHASE4":2654,"NA":2656},{"trials":2643,"activeCount":99},[],{"trials":2645,"activeCount":99},[],{"trials":2647,"activeCount":99},[2648],{"nctId":1838,"briefTitle":1839,"status":107,"phases":2649,"primaryCompletion":1841,"completion":1841,"start":1842,"enrollment":99,"conditions":2650,"interventions":2651},[87,88],[1844,1845,1846],[1848,1818],{"trials":2653,"activeCount":99},[],{"trials":2655,"activeCount":99},[],{"trials":2657,"activeCount":99},[],{"intervention":2659,"totalTrials":132,"cells":2660},"Lenvatinib + Denosumab",{"EARLY_PHASE1":2661,"PHASE1":2663,"PHASE2":2665,"PHASE3":2678,"PHASE4":2680,"NA":2682},{"trials":2662,"activeCount":99},[],{"trials":2664,"activeCount":99},[],{"trials":2666,"activeCount":99},[2667],{"nctId":2668,"briefTitle":2669,"status":149,"phases":2670,"primaryCompletion":2671,"completion":2672,"start":2673,"enrollment":2674,"conditions":2675,"interventions":2677},"NCT03732495","Study of the Efficacy of Lenvatinib Combined With Denosumab in the Treatment of Patients With Predominant Bone Metastatic Radioiodine Refractory Differentiated Thyroid Carcinomas",[88],"2022-12-15","2023-01-15","2019-07-26",35,[2676],"Thyroid Cancer Metastatic",[2659],{"trials":2679,"activeCount":99},[],{"trials":2681,"activeCount":99},[],{"trials":2683,"activeCount":99},[],{"intervention":2685,"totalTrials":132,"cells":2686},"177Lu-PSMA-1",{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2702,"PHASE4":2704,"NA":2706},{"trials":2688,"activeCount":99},[],{"trials":2690,"activeCount":99},[],{"trials":2692,"activeCount":99},[2693],{"nctId":2694,"briefTitle":2695,"status":416,"phases":2696,"primaryCompletion":2697,"completion":2697,"start":2698,"enrollment":24,"conditions":2699,"interventions":2701},"NCT06059014","Phase I\u002FII Study Evaluating PSMA Targeted Radionuclide Therapy in Adult Patients With Metastatic Clear Cell Renal Cancer",[87,88],"2025-07-16","2023-11-09",[2700],"Metastatic Clear Cell Renal Cell Carcinoma",[2685],{"trials":2703,"activeCount":99},[],{"trials":2705,"activeCount":99},[],{"trials":2707,"activeCount":99},[],{"intervention":2709,"totalTrials":132,"cells":2710},"Everolimus 2.5 mg\u002Fday",{"EARLY_PHASE1":2711,"PHASE1":2713,"PHASE2":2715,"PHASE3":2728,"PHASE4":2730,"NA":2732},{"trials":2712,"activeCount":99},[],{"trials":2714,"activeCount":99},[],{"trials":2716,"activeCount":99},[2717],{"nctId":2718,"briefTitle":2719,"status":2720,"phases":2721,"primaryCompletion":2722,"completion":2723,"start":2724,"enrollment":674,"conditions":2725,"interventions":2726},"NCT02008019","A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas","SUSPENDED",[88],"2018-08","2019-08","2014-08-14",[1368],[2709,2727],"Everolimus 10 mg\u002Fday",{"trials":2729,"activeCount":99},[],{"trials":2731,"activeCount":99},[],{"trials":2733,"activeCount":99},[],{"intervention":2727,"totalTrials":132,"cells":2735},{"EARLY_PHASE1":2736,"PHASE1":2738,"PHASE2":2740,"PHASE3":2746,"PHASE4":2748,"NA":2750},{"trials":2737,"activeCount":99},[],{"trials":2739,"activeCount":99},[],{"trials":2741,"activeCount":99},[2742],{"nctId":2718,"briefTitle":2719,"status":2720,"phases":2743,"primaryCompletion":2722,"completion":2723,"start":2724,"enrollment":674,"conditions":2744,"interventions":2745},[88],[1368],[2709,2727],{"trials":2747,"activeCount":99},[],{"trials":2749,"activeCount":99},[],{"trials":2751,"activeCount":99},[],{"intervention":2753,"totalTrials":132,"cells":2754},"MK2206",{"EARLY_PHASE1":2755,"PHASE1":2757,"PHASE2":2759,"PHASE3":2769,"PHASE4":2771,"NA":2773},{"trials":2756,"activeCount":99},[],{"trials":2758,"activeCount":99},[],{"trials":2760,"activeCount":99},[2761],{"nctId":2762,"briefTitle":2763,"status":546,"phases":2764,"primaryCompletion":2361,"completion":1288,"start":2765,"enrollment":1937,"conditions":2766,"interventions":2768},"NCT01466868","Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma",[88],"2011-11",[2767],"Diffuse Large B Cell Lymphoma",[2753],{"trials":2770,"activeCount":99},[],{"trials":2772,"activeCount":99},[],{"trials":2774,"activeCount":99},[],{"intervention":689,"totalTrials":132,"cells":2776},{"EARLY_PHASE1":2777,"PHASE1":2779,"PHASE2":2781,"PHASE3":2787,"PHASE4":2789,"NA":2791},{"trials":2778,"activeCount":99},[],{"trials":2780,"activeCount":99},[],{"trials":2782,"activeCount":99},[2783],{"nctId":681,"briefTitle":682,"status":546,"phases":2784,"primaryCompletion":684,"completion":684,"start":685,"enrollment":132,"conditions":2785,"interventions":2786},[87,88],[687],[660,689,690],{"trials":2788,"activeCount":99},[],{"trials":2790,"activeCount":99},[],{"trials":2792,"activeCount":99},[],{"intervention":690,"totalTrials":132,"cells":2794},{"EARLY_PHASE1":2795,"PHASE1":2797,"PHASE2":2799,"PHASE3":2805,"PHASE4":2807,"NA":2809},{"trials":2796,"activeCount":99},[],{"trials":2798,"activeCount":99},[],{"trials":2800,"activeCount":99},[2801],{"nctId":681,"briefTitle":682,"status":546,"phases":2802,"primaryCompletion":684,"completion":684,"start":685,"enrollment":132,"conditions":2803,"interventions":2804},[87,88],[687],[660,689,690],{"trials":2806,"activeCount":99},[],{"trials":2808,"activeCount":99},[],{"trials":2810,"activeCount":99},[],{"intervention":2812,"totalTrials":132,"cells":2813},"Lenvatinib",{"EARLY_PHASE1":2814,"PHASE1":2816,"PHASE2":2818,"PHASE3":2830,"PHASE4":2832,"NA":2834},{"trials":2815,"activeCount":99},[],{"trials":2817,"activeCount":99},[],{"trials":2819,"activeCount":99},[2820],{"nctId":2821,"briefTitle":2822,"status":416,"phases":2823,"primaryCompletion":2824,"completion":2825,"start":2470,"enrollment":2826,"conditions":2827,"interventions":2829},"NCT04193553","Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib\u002FSunitinib Failure",[88],"2024-01-30","2024-04-26",77,[2828],"Gastro Intestinal Stromal Tumour",[2812],{"trials":2831,"activeCount":99},[],{"trials":2833,"activeCount":99},[],{"trials":2835,"activeCount":99},[],{"intervention":2837,"totalTrials":132,"cells":2838},"Injection of Pegfilgrastim",{"EARLY_PHASE1":2839,"PHASE1":2841,"PHASE2":2843,"PHASE3":2857,"PHASE4":2859,"NA":2861},{"trials":2840,"activeCount":99},[],{"trials":2842,"activeCount":99},[],{"trials":2844,"activeCount":99},[2845],{"nctId":2846,"briefTitle":2847,"status":416,"phases":2848,"primaryCompletion":1451,"completion":2849,"start":2850,"enrollment":2851,"conditions":2852,"interventions":2855},"NCT00794261","Stem Cell Mobilization With Pegfilgrastim in Lymphoma and Myeloma",[88],"2010-06","2008-09",150,[2853,2854],"Lymphoma","Myeloma",[2837,2856],"Injection of Filgrastim",{"trials":2858,"activeCount":99},[],{"trials":2860,"activeCount":99},[],{"trials":2862,"activeCount":99},[],{"intervention":2856,"totalTrials":132,"cells":2864},{"EARLY_PHASE1":2865,"PHASE1":2867,"PHASE2":2869,"PHASE3":2875,"PHASE4":2877,"NA":2879},{"trials":2866,"activeCount":99},[],{"trials":2868,"activeCount":99},[],{"trials":2870,"activeCount":99},[2871],{"nctId":2846,"briefTitle":2847,"status":416,"phases":2872,"primaryCompletion":1451,"completion":2849,"start":2850,"enrollment":2851,"conditions":2873,"interventions":2874},[88],[2853,2854],[2837,2856],{"trials":2876,"activeCount":99},[],{"trials":2878,"activeCount":99},[],{"trials":2880,"activeCount":99},[],{"intervention":2882,"totalTrials":132,"cells":2883},"Axitinib",{"EARLY_PHASE1":2884,"PHASE1":2886,"PHASE2":2888,"PHASE3":2899,"PHASE4":2901,"NA":2903},{"trials":2885,"activeCount":99},[],{"trials":2887,"activeCount":99},[],{"trials":2889,"activeCount":99},[2890],{"nctId":2891,"briefTitle":2892,"status":416,"phases":2893,"primaryCompletion":2894,"completion":2894,"start":2895,"enrollment":2561,"conditions":2896,"interventions":2898},"NCT02489695","Axitinib in1st Line Treatment for Patients With Advanced or Metastatic Papillary Renal Cell Carcinoma",[88],"2019-07","2015-10",[2897],"Papillary Renal Cell Carcinoma",[2882],{"trials":2900,"activeCount":99},[],{"trials":2902,"activeCount":99},[],{"trials":2904,"activeCount":99},[],{"intervention":2906,"totalTrials":132,"cells":2907},"Xenon",{"EARLY_PHASE1":2908,"PHASE1":2910,"PHASE2":2912,"PHASE3":2923,"PHASE4":2925,"NA":2927},{"trials":2909,"activeCount":99},[],{"trials":2911,"activeCount":99},[],{"trials":2913,"activeCount":99},[2914],{"nctId":2915,"briefTitle":2916,"status":416,"phases":2917,"primaryCompletion":2493,"completion":2493,"start":2918,"enrollment":2919,"conditions":2920,"interventions":2921},"NCT01696630","Xenon Combined With Intraoperative Thoracic Epidural Analgesia",[88],"2012-10",31,[18],[2906,2922],"Desflurane",{"trials":2924,"activeCount":99},[],{"trials":2926,"activeCount":99},[],{"trials":2928,"activeCount":99},[],{"intervention":2922,"totalTrials":132,"cells":2930},{"EARLY_PHASE1":2931,"PHASE1":2933,"PHASE2":2935,"PHASE3":2941,"PHASE4":2943,"NA":2945},{"trials":2932,"activeCount":99},[],{"trials":2934,"activeCount":99},[],{"trials":2936,"activeCount":99},[2937],{"nctId":2915,"briefTitle":2916,"status":416,"phases":2938,"primaryCompletion":2493,"completion":2493,"start":2918,"enrollment":2919,"conditions":2939,"interventions":2940},[88],[18],[2906,2922],{"trials":2942,"activeCount":99},[],{"trials":2944,"activeCount":99},[],{"trials":2946,"activeCount":99},[],{"intervention":2948,"totalTrials":132,"cells":2949},"Pexidartinib",{"EARLY_PHASE1":2950,"PHASE1":2952,"PHASE2":2965,"PHASE3":2967,"PHASE4":2969,"NA":2971},{"trials":2951,"activeCount":99},[],{"trials":2953,"activeCount":99},[2954],{"nctId":2955,"briefTitle":2956,"status":416,"phases":2957,"primaryCompletion":2211,"completion":2958,"start":2959,"enrollment":2960,"conditions":2961,"interventions":2963},"NCT02777710","Evaluation of Safety and Activity of an Anti-PDL1 Antibody (DURVALUMAB) Combined With CSF-1R TKI (PEXIDARTINIB) in Patients With Metastatic\u002FAdvanced Pancreatic or Colorectal Cancers",[87],"2019-12","2016-06",48,[18,2962,28,26],"Pancreatic Cancer",[2948,2964],"Durvalumab",{"trials":2966,"activeCount":99},[],{"trials":2968,"activeCount":99},[],{"trials":2970,"activeCount":99},[],{"trials":2972,"activeCount":99},[],{"intervention":2964,"totalTrials":132,"cells":2974},{"EARLY_PHASE1":2975,"PHASE1":2977,"PHASE2":2983,"PHASE3":2985,"PHASE4":2987,"NA":2989},{"trials":2976,"activeCount":99},[],{"trials":2978,"activeCount":99},[2979],{"nctId":2955,"briefTitle":2956,"status":416,"phases":2980,"primaryCompletion":2211,"completion":2958,"start":2959,"enrollment":2960,"conditions":2981,"interventions":2982},[87],[18,2962,28,26],[2948,2964],{"trials":2984,"activeCount":99},[],{"trials":2986,"activeCount":99},[],{"trials":2988,"activeCount":99},[],{"trials":2990,"activeCount":99},[],{"intervention":2992,"totalTrials":132,"cells":2993},"OTSA101-DTPA-90Y level 1",{"EARLY_PHASE1":2994,"PHASE1":2996,"PHASE2":3011,"PHASE3":3013,"PHASE4":3015,"NA":3017},{"trials":2995,"activeCount":99},[],{"trials":2997,"activeCount":99},[2998],{"nctId":2999,"briefTitle":3000,"status":546,"phases":3001,"primaryCompletion":3002,"completion":3003,"start":3004,"enrollment":3005,"conditions":3006,"interventions":3008},"NCT01469975","First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10",[87],"2015-02-03","2015-06-30","2011-12",20,[3007],"Sarcoma, Synovial",[2992,3009,3010],"OTSA101-DTPA-90Y level 2","OTSA101-DTPA-90Y level 3",{"trials":3012,"activeCount":99},[],{"trials":3014,"activeCount":99},[],{"trials":3016,"activeCount":99},[],{"trials":3018,"activeCount":99},[],{"intervention":3009,"totalTrials":132,"cells":3020},{"EARLY_PHASE1":3021,"PHASE1":3023,"PHASE2":3029,"PHASE3":3031,"PHASE4":3033,"NA":3035},{"trials":3022,"activeCount":99},[],{"trials":3024,"activeCount":99},[3025],{"nctId":2999,"briefTitle":3000,"status":546,"phases":3026,"primaryCompletion":3002,"completion":3003,"start":3004,"enrollment":3005,"conditions":3027,"interventions":3028},[87],[3007],[2992,3009,3010],{"trials":3030,"activeCount":99},[],{"trials":3032,"activeCount":99},[],{"trials":3034,"activeCount":99},[],{"trials":3036,"activeCount":99},[],{"intervention":3010,"totalTrials":132,"cells":3038},{"EARLY_PHASE1":3039,"PHASE1":3041,"PHASE2":3047,"PHASE3":3049,"PHASE4":3051,"NA":3053},{"trials":3040,"activeCount":99},[],{"trials":3042,"activeCount":99},[3043],{"nctId":2999,"briefTitle":3000,"status":546,"phases":3044,"primaryCompletion":3002,"completion":3003,"start":3004,"enrollment":3005,"conditions":3045,"interventions":3046},[87],[3007],[2992,3009,3010],{"trials":3048,"activeCount":99},[],{"trials":3050,"activeCount":99},[],{"trials":3052,"activeCount":99},[],{"trials":3054,"activeCount":99},[],{"intervention":3056,"totalTrials":132,"cells":3057},"Association of Bevacizumab",{"EARLY_PHASE1":3058,"PHASE1":3060,"PHASE2":3070,"PHASE3":3072,"PHASE4":3074,"NA":3076},{"trials":3059,"activeCount":99},[],{"trials":3061,"activeCount":99},[3062],{"nctId":3063,"briefTitle":3064,"status":416,"phases":3065,"primaryCompletion":2386,"completion":2103,"start":3066,"enrollment":809,"conditions":3067,"interventions":3069},"NCT01202032","Multicenter Dose-escalation Study of a Combination of Pazopanib and Bevacizumab in Patients With Metastatic Renal Cell Carcinoma or Others Advanced Solid Tumors",[87],"2010-07",[30,3068],"Advanced Refractory Solid Tumors Histologically or Cytologically Confirmed",[3056],{"trials":3071,"activeCount":99},[],{"trials":3073,"activeCount":99},[],{"trials":3075,"activeCount":99},[],{"trials":3077,"activeCount":99},[],{"intervention":592,"totalTrials":132,"cells":3079},{"EARLY_PHASE1":3080,"PHASE1":3082,"PHASE2":3088,"PHASE3":3090,"PHASE4":3092,"NA":3094},{"trials":3081,"activeCount":99},[],{"trials":3083,"activeCount":99},[3084],{"nctId":580,"briefTitle":581,"status":416,"phases":3085,"primaryCompletion":583,"completion":584,"start":585,"enrollment":586,"conditions":3086,"interventions":3087},[87],[588,589,590],[40,592],{"trials":3089,"activeCount":99},[],{"trials":3091,"activeCount":99},[],{"trials":3093,"activeCount":99},[],{"trials":3095,"activeCount":99},[],{"intervention":3097,"totalTrials":132,"cells":3098},"NP137 DL and RP2D",{"EARLY_PHASE1":3099,"PHASE1":3101,"PHASE2":3113,"PHASE3":3115,"PHASE4":3117,"NA":3119},{"trials":3100,"activeCount":99},[],{"trials":3102,"activeCount":99},[3103],{"nctId":3104,"briefTitle":3105,"status":416,"phases":3106,"primaryCompletion":3107,"completion":3108,"start":3109,"enrollment":536,"conditions":3110,"interventions":3112},"NCT02977195","First in Human Evaluation of Safety, Pharmacokinetics, and Clinical Activity of a Monoclonal Antibody Targeting Netrin 1 in Patients With Advanced\u002FMetastatic Solid Tumors",[87],"2021-12","2022-06","2017-01-09",[1330,1844,3111],"Hormone Receptor Positive",[3097],{"trials":3114,"activeCount":99},[],{"trials":3116,"activeCount":99},[],{"trials":3118,"activeCount":99},[],{"trials":3120,"activeCount":99},[],{"intervention":1942,"totalTrials":132,"cells":3122},{"EARLY_PHASE1":3123,"PHASE1":3125,"PHASE2":3131,"PHASE3":3133,"PHASE4":3135,"NA":3137},{"trials":3124,"activeCount":99},[],{"trials":3126,"activeCount":99},[3127],{"nctId":1931,"briefTitle":1932,"status":416,"phases":3128,"primaryCompletion":1934,"completion":1935,"start":1936,"enrollment":1937,"conditions":3129,"interventions":3130},[87],[1939,1940],[1942,158],{"trials":3132,"activeCount":99},[],{"trials":3134,"activeCount":99},[],{"trials":3136,"activeCount":99},[],{"trials":3138,"activeCount":99},[],{"intervention":3140,"totalTrials":132,"cells":3141},"Immunological and tumour characterization",{"EARLY_PHASE1":3142,"PHASE1":3144,"PHASE2":3146,"PHASE3":3148,"PHASE4":3150,"NA":3152},{"trials":3143,"activeCount":99},[],{"trials":3145,"activeCount":99},[],{"trials":3147,"activeCount":99},[],{"trials":3149,"activeCount":99},[],{"trials":3151,"activeCount":99},[],{"trials":3153,"activeCount":99},[3154],{"nctId":3155,"briefTitle":3156,"status":149,"phases":3157,"primaryCompletion":3158,"completion":1518,"start":3159,"enrollment":3160,"conditions":3161,"interventions":3163},"NCT03628859","BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer)",[],"2023-06","2018-12-21",30,[3162],"Renal Cancer Metastatic",[3140],{"intervention":3165,"totalTrials":132,"cells":3166},"Medical Analgesics",{"EARLY_PHASE1":3167,"PHASE1":3169,"PHASE2":3171,"PHASE3":3173,"PHASE4":3175,"NA":3177},{"trials":3168,"activeCount":99},[],{"trials":3170,"activeCount":99},[],{"trials":3172,"activeCount":99},[],{"trials":3174,"activeCount":99},[],{"trials":3176,"activeCount":99},[],{"trials":3178,"activeCount":99},[3179],{"nctId":3180,"briefTitle":3181,"status":546,"phases":3182,"primaryCompletion":3183,"completion":3184,"start":3185,"enrollment":3186,"conditions":3187,"interventions":3189},"NCT03441139","Efficacy of Cryotherapy Combined or Not With Analgesics in Uncontrolled Painful Musculoskeletal Metastasis",[91],"2020-05-30","2020-08-30","2018-07-19",18,[3188],"Musculoskeletal Pain",[3165],{"intervention":3191,"totalTrials":132,"cells":3192},"Blood and tumor sample",{"EARLY_PHASE1":3193,"PHASE1":3195,"PHASE2":3197,"PHASE3":3199,"PHASE4":3201,"NA":3203},{"trials":3194,"activeCount":99},[],{"trials":3196,"activeCount":99},[],{"trials":3198,"activeCount":99},[],{"trials":3200,"activeCount":99},[],{"trials":3202,"activeCount":99},[],{"trials":3204,"activeCount":99},[3205],{"nctId":3206,"briefTitle":3207,"status":149,"phases":3208,"primaryCompletion":3209,"completion":3210,"start":3004,"enrollment":853,"conditions":3211,"interventions":3212},"NCT01440413","Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer",[91],"2018-12","2020-12",[15],[3191],{"intervention":3214,"totalTrials":132,"cells":3215},"Patient treated by Avapritinib in real life",{"EARLY_PHASE1":3216,"PHASE1":3218,"PHASE2":3220,"PHASE3":3222,"PHASE4":3224,"NA":3226},{"trials":3217,"activeCount":99},[],{"trials":3219,"activeCount":99},[],{"trials":3221,"activeCount":99},[],{"trials":3223,"activeCount":99},[],{"trials":3225,"activeCount":99},[],{"trials":3227,"activeCount":99},[3228],{"nctId":3229,"briefTitle":3230,"status":149,"phases":3231,"primaryCompletion":3232,"completion":3233,"start":3234,"enrollment":1878,"conditions":3235,"interventions":3238},"NCT04927260","French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients",[],"2024-04-30","2024-12-31","2021-03-31",[422,3236,3237],"GIST, Malignant","PDGFR-Alpha D842V",[3214],{"intervention":3240,"totalTrials":132,"cells":3241},"Ropivacaine",{"EARLY_PHASE1":3242,"PHASE1":3244,"PHASE2":3246,"PHASE3":3248,"PHASE4":3250,"NA":3252},{"trials":3243,"activeCount":99},[],{"trials":3245,"activeCount":99},[],{"trials":3247,"activeCount":99},[],{"trials":3249,"activeCount":99},[],{"trials":3251,"activeCount":99},[],{"trials":3253,"activeCount":99},[3254],{"nctId":3255,"briefTitle":3256,"status":416,"phases":3257,"primaryCompletion":3258,"completion":3259,"start":3260,"enrollment":3261,"conditions":3262,"interventions":3266},"NCT01194843","Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Infiltrations",[91],"2014-02","2015-04","2009-03",85,[3263,3264,3265],"Hepatectomy","Pain","Metastasis",[3240,3267],"Physiological serum",{"intervention":3267,"totalTrials":132,"cells":3269},{"EARLY_PHASE1":3270,"PHASE1":3272,"PHASE2":3274,"PHASE3":3276,"PHASE4":3278,"NA":3280},{"trials":3271,"activeCount":99},[],{"trials":3273,"activeCount":99},[],{"trials":3275,"activeCount":99},[],{"trials":3277,"activeCount":99},[],{"trials":3279,"activeCount":99},[],{"trials":3281,"activeCount":99},[3282],{"nctId":3255,"briefTitle":3256,"status":416,"phases":3283,"primaryCompletion":3258,"completion":3259,"start":3260,"enrollment":3261,"conditions":3284,"interventions":3285},[91],[3263,3264,3265],[3240,3267],{"intervention":3287,"totalTrials":132,"cells":3288},"Breast cancer cohort",{"EARLY_PHASE1":3289,"PHASE1":3291,"PHASE2":3293,"PHASE3":3295,"PHASE4":3297,"NA":3299},{"trials":3290,"activeCount":99},[],{"trials":3292,"activeCount":99},[],{"trials":3294,"activeCount":99},[],{"trials":3296,"activeCount":99},[],{"trials":3298,"activeCount":99},[],{"trials":3300,"activeCount":99},[3301],{"nctId":3302,"briefTitle":3303,"status":416,"phases":3304,"primaryCompletion":3305,"completion":3305,"start":3066,"enrollment":3306,"conditions":3307,"interventions":3309},"NCT01306188","Prognostic Value of Divpenia and CD4 Count in Relapsed Breast or Lung Cancer Patients",[],"2014-12",179,[15,3308],"Lung Cancer",[3287,3310],"Lung cancer cohort",{"intervention":3310,"totalTrials":132,"cells":3312},{"EARLY_PHASE1":3313,"PHASE1":3315,"PHASE2":3317,"PHASE3":3319,"PHASE4":3321,"NA":3323},{"trials":3314,"activeCount":99},[],{"trials":3316,"activeCount":99},[],{"trials":3318,"activeCount":99},[],{"trials":3320,"activeCount":99},[],{"trials":3322,"activeCount":99},[],{"trials":3324,"activeCount":99},[3325],{"nctId":3302,"briefTitle":3303,"status":416,"phases":3326,"primaryCompletion":3305,"completion":3305,"start":3066,"enrollment":3306,"conditions":3327,"interventions":3328},[],[15,3308],[3287,3310],{"intervention":3330,"totalTrials":132,"cells":3331},"Ketamine use in CLCC sites",{"EARLY_PHASE1":3332,"PHASE1":3334,"PHASE2":3336,"PHASE3":3338,"PHASE4":3340,"NA":3342},{"trials":3333,"activeCount":99},[],{"trials":3335,"activeCount":99},[],{"trials":3337,"activeCount":99},[],{"trials":3339,"activeCount":99},[],{"trials":3341,"activeCount":99},[],{"trials":3343,"activeCount":99},[3344],{"nctId":3345,"briefTitle":3346,"status":416,"phases":3347,"primaryCompletion":3348,"completion":3349,"start":3350,"enrollment":420,"conditions":3351,"interventions":3355},"NCT04459234","Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC",[],"2023-02-06","2023-03-09","2021-02-02",[21,3352,3353,3354],"Chronic Pain","Neuropathic Pain","Opioid Use",[3330],{"intervention":3357,"totalTrials":132,"cells":3358},"Questionnaire, blood, urine, hair and dust samplings",{"EARLY_PHASE1":3359,"PHASE1":3361,"PHASE2":3363,"PHASE3":3365,"PHASE4":3367,"NA":3369},{"trials":3360,"activeCount":99},[],{"trials":3362,"activeCount":99},[],{"trials":3364,"activeCount":99},[],{"trials":3366,"activeCount":99},[],{"trials":3368,"activeCount":99},[],{"trials":3370,"activeCount":99},[3371],{"nctId":3372,"briefTitle":3373,"status":416,"phases":3374,"primaryCompletion":3375,"completion":3375,"start":3376,"enrollment":3377,"conditions":3378,"interventions":3380},"NCT02986763","Evaluation of Pesticide Exposure in the General Population",[],"2017-03","2015-06",166,[3379],"Pesticide Poisoning",[3357],{"intervention":3382,"totalTrials":132,"cells":3383},"Bevacizumab + blood samples",{"EARLY_PHASE1":3384,"PHASE1":3386,"PHASE2":3388,"PHASE3":3390,"PHASE4":3392,"NA":3394},{"trials":3385,"activeCount":99},[],{"trials":3387,"activeCount":99},[],{"trials":3389,"activeCount":99},[],{"trials":3391,"activeCount":99},[],{"trials":3393,"activeCount":99},[],{"trials":3395,"activeCount":99},[3396],{"nctId":3397,"briefTitle":3398,"status":416,"phases":3399,"primaryCompletion":1449,"completion":1449,"start":3400,"enrollment":3401,"conditions":3402,"interventions":3403},"NCT01405430","Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab",[91],"2010-05",63,[18,3265],[3382],{"intervention":1295,"totalTrials":132,"cells":3405},{"EARLY_PHASE1":3406,"PHASE1":3408,"PHASE2":3410,"PHASE3":3412,"PHASE4":3414,"NA":3416},{"trials":3407,"activeCount":99},[],{"trials":3409,"activeCount":99},[],{"trials":3411,"activeCount":99},[],{"trials":3413,"activeCount":99},[],{"trials":3415,"activeCount":99},[],{"trials":3417,"activeCount":99},[3418],{"nctId":1285,"briefTitle":1286,"status":546,"phases":3419,"primaryCompletion":1288,"completion":1289,"start":1290,"enrollment":1291,"conditions":3420,"interventions":3421},[91],[1293],[1259,1295]]